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Supervisory Professor: Joya Chandra, Ph.D.  
Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that primarily act 
upon acetylation of histones, however they also increase levels of intracellular reactive 
oxygen species (ROS).  We hypothesized that agents that cause oxidative stress 
might enhance the efficacy of HDACi.  To test this hypothesis, we treated acute 
lymphocytic leukemia cells (ALL) with HDACi and adaphostin (ROS generating agent).  
The combination of two different HDACi (vorinostat or entinostat) with adaphostin 
synergistically induced apoptosis in ALL. This synergistic effect was blocked when 
cells were pre-treated with the caspase-9 inhibitor, LEHD.  In addition, we showed that 
loss of the mitochondrial membrane potential is the earliest event observed starting at 
12 h.  Following this event, we observed increased levels of superoxide at 16 h, and 
ultimately caspase-3 activation.  Pre-treatment with the antioxidant N-acetylcysteine 
(NAC) blocked ROS generation and reversed the loss of mitochondrial membrane 
potential for both combinations.  Interestingly, DNA fragmentation and caspase-3 
activity was only blocked by NAC in cells treated with vorinostat-adaphostin; but not 
with entinostat-adaphostin.  These results suggest that different redox mechanisms 
are involved in the induction of ROS-mediated apoptosis.  To further understand these 
events, we studied the role of the antioxidants glutathione (GSH) and thioredoxin (Trx).  
We found that the combination of entinostat-adaphostin induced acetylation of the 
 vi 
antioxidant thioredoxin (Trx) and decreased intracellular levels of GSH.  However, no 
effect on Trx activity was observed in either combination. In addition, pre-treatment 
with GSH ethyl ester, a soluble form of GSH, did not block DNA fragmentation.  
Together these results suggested that GSH and Trx are not major players in the 
induction of oxidative stress.  Array data examining the expression of genes involved 
in oxidative stress demonstrated a differential regulation between cells treated with 
vorinostat-adaphostin and entinostat-adaphostin.  Some of the genes differentially 
expressed between the combinations include aldehyde oxidase 1, glutathione 
peroxidase-5, -6, peroxiredoxin 6 and myeloperoxidase.  Taken together, these 
experimental results indicate that the synergistic activity of two different HDACi with 
adaphostin is mediated by distinct redox mechanisms in ALL cells.  Understanding the 
mechanism involved in these combinations will advance scientific knowledge of how 
the action of HDACi could be augmented in leukemia models. Moreover, this 
information could be used for the development of effective clinical trials combining 
HDACi with other anticancer agents. 
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CHAPTER 1:  INTRODUCTION 
1.1      Leukemia 
Despite improvements in medicine, cancer remains one of the leading causes 
of death in the U.S. It is estimated that in 2012, about 1.6 million new cases of cancer 
will be diagnosed in the U.S. and one of four deaths will be due to cancer [3].  Among 
these new cases, approximately one third will be amongst the pediatric population.  
Within this population, leukemia is the cancer with the highest incidence and mortality 
among pediatric patients [3].  
Leukemia by definition is a cancer of the blood and bone marrow cells [4].  This 
type of cancer is usually classified based on the cell type or by how rapidly the disease 
progress or develops.  In the case of the cell type, these can be: lymphocytic 
leukemias, which are developed from the lymphoid precursors or myeloid leukemias, 
which are developed from the myeloid precursors (Figure 1).  In terms of disease 
progression, these can be divided into acute versus chronic leukemias.  The term 
acute refers to a rapid tumor cell proliferation and accumulation of immature or blast 
cells (lymphoblasts or myeloblasts).  In the case of chronic leukemias, the 
predominant tumor cells are mature blood cells and are characterized by a slow 
growth rate.  Based on this basic definition there are four major types of leukemias: 
acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic 
leukemia (CLL) and chronic myeloid leukemia (CML) [4]. 
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Figure 1.  Origin of the major four classes of leukemias. Normal hematopoiesis 
(the formation of the blood) is a process where the hematopoietic stem cells (HSCs) 
differentiate into two common lineages: common lymphoid progenitors (CLP) and 
common myeloid progenitors (CMP).  Acute Lymphoblastic Leukemia (ALL) and 
Chronic Lymphoblastic Leukemia (CLL) are derived from the CLP.  In contrast, 
Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) are 
derived from the CMP.  Adapted from Irwin M.E. et al. Antioxidant and Redox 
Signaling 2012 Sep 28 [Epub ahead of print] [1]. 
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The most common type of leukemias in children are acute leukemias, with ALL 
being the most common subtype.  ALL comprises 80% of all childhood leukemias 
while AML accounts for approximately 18%.  In terms of chronic leukemias, only about 
2% of CML is diagnosed in children and CLL is rarely reported in pediatric patients [5].  
The major cause of childhood leukemias has been linked to genetic factors and/or 
environmental factors.  Some of the genetic factors include hyperdiploidy, 
hypodiploidy, chromosomal translocations and deletions [6].  In addition to these 
genetic abnormalities, several studies have found an association between genetic 
syndromes and the development of childhood leukemia.  Some of these syndromes 
include: Down syndrome, neurofibromatosis and schwachman syndrome [7-9].  
Environmental factors like in utero exposure to ionizing radiation; exposure to certain 
chemicals like benzene, hydrocarbons and pesticides has also been linked to the 
development of childhood leukemias [10, 11].   
ALL is divided into different subtypes based upon morphological and 
cytogenetic features.  In terms of morphological changes, ALL can be divided into 
three subtypes: ALL-L1, -L2 and -L3 [4].  In the L1 subtype the lymphoblast is relative 
small with a high nuclear to cytoplasmic ratio and small nucleoli.  In L2 the lymphoblast 
is larger with low nuclear to cytoplasmic ratio and large nucleoli.  In L3 the lymphoblast 
resemble a mature B cell with large vacuoles and nucleoli.  Each of these subtypes 
are further divided by immunologic types: pre-B cells and pre-T cells [4].   
Advances in the molecular genetics field have resulted in more accurate 
classification of ALL based on their genetic abnormalities.  These cytogenetic 
classifications have helped to understand better the prognosis of ALL.  Some of the 
cytogenetic features with good prognosis observed in ALL include: hyperdiploidy 
(more than 50 chromosomes) and translocations like t(12;21)(p21;q22).  Otherwise 
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cytogenetic features with intermediate and poor prognosis include: hypodiploidy (less 
than 45 chromosomes), del(6q), del(9p), t(9;22)(q34;q11) and t(8;14)(q24;q32) [4].  
During the past few decades, great advances in the treatment of pediatric 
leukemia has resulted in an 80% cure rate [12].  The treatment for pediatric leukemias 
varies according to age, disease stage, subtype and myeloid versus lymphoid origin.  
Standard treatment for leukemia includes chemotherapy, radiation, bone marrow 
transplantation, stem cell transplantation or a combination of these treatments [13].  
Usually chemotherapy regimens are divided in three major stages or phases: 
induction, consolidation and maintenance phase [13].  During induction phase, the 
major goal is to kill the majority of the cancer cells.  The duration of this phase is 
around three to eight weeks and during this time different chemotherapies are 
administered.  The second phase is consolidation where the major goal is to eliminate 
any remaining cancer cells.  The duration of this phase is around a few months.  
Finally after remission of the disease, the third phase of maintenance begins.  This is a 
less intense phase and may last around one to two years.  The major goal in this 
phase is to decrease the probability of relapse.   
During all these phases different types of drugs are administrated.  Since 
cancer cells are characterized by abnormal proliferation, the majority of the drugs used 
work by disrupting cell proliferation and progression of cell cycle.  Some of the drugs 
most commonly used include anthracyclines, topoisomerase inhibitors and 
antimetabolites [13].  Anthracyclines like daunorubicin and doxorubicin are commonly 
used during induction phase and work by intercalating between base pair of the DNA 
inhibiting its synthesis.  In addition some of these drugs can act as topoisomerase 
inhibitors, in this case the agent binds to the topoisomerase molecule blocking its 
ability to bind to the DNA, which ultimately results in DNA damage and cell death.  In 
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the case of antimetabolites like methotrexate and thioguanine, these drugs work by 
preventing purines and pyrimidines to incorporate into DNA during S phase, 
preventing cell division and growth.    
Even when cure rates are promising, 20% of pediatric patients with ALL are not 
curable due to specific molecular subtypes, which confer resistance to the current 
available chemotherapy.  Furthermore, studies have demonstrated that survivors from 
pediatric leukemias tend to develop treatment related side effects later in life [14].  
Some of the side effects observed include cardiotoxicity and the development of 
secondary cancers.  In addition, even though ALL affects mostly pediatric patients, 
there is a group of adults that will develop ALL during the course of their life.  The 
prognosis in these patients is not as promising as in children, resulting in a survival 
rate less than 40% [4].  For these groups of patients, the development of new selective 
drugs and strategies for the treatment of ALL is of great importance.   
Conventional therapies, like the ones mentioned before, kill cancer cells by 
inhibiting growth.  However, this inhibition is not specific for cancer cells; these drugs 
can also target normal cells that are actively dividing.  Therefore, development of 
specific targeted therapies based on differences between cancer and normal cells is of 
utmost importance.  The identification of specific subtypes and alterations in cancer 
cells have helped in the development of new targeted therapies.  Some of the targeted 
therapies that have shown promise for the treatment of leukemias include: kinase 
inhibitors, histone deacetylase inhibitors, proteasome inhibitors and Bcl-2-targeted 
agents [15].  Interestingly, in addition to inhibiting their specific targets, some of these 
agents have been shown to alter the redox state of cancer cells [15, 16].  The following 
section will be dedicated to introduce the concept of oxidative stress and its 
implications for the treatment of cancer.  
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1.2      Oxidative stress 
1.2.1 Redox homeostasis and oxidative stress 
Redox homeostasis is defined as the balance between the production and 
elimination of oxygen-containing molecules named reactive oxygen species (ROS) 
[16].  ROS are highly reactive molecules that include radical species like superoxide 
and hydroxyl radical and non-radical molecules like hydrogen peroxide.  The 
production of ROS within the cell is the result of different exogenous and endogenous 
stimuli.  Exogenous sources of ROS include exposure to different chemicals and 
radiation.  The major endogenous source of cellular ROS is the mitochondria, where 
superoxide is generated by the electron-transport chain and subsequent reactions 
result in the production of hydrogen peroxide and hydroxyl radical [16].  Other 
endogenous sources of ROS include the activation of oxidases including NADPH 
oxidase, xanthine oxidase and monoamine oxidase [16].   
Proper redox homeostasis plays a critical role for the normal function of the cell.  
To maintain redox homeostasis, cells contain different antioxidant systems that help to 
eliminate excessive levels of ROS.  Some of these antioxidants include enzymes like 
superoxide dismutase (SOD), which catalyze the conversion of superoxide to 
hydrogen peroxide and catalase.  Subsequently catalase, another antioxidant, 
catalyzes the conversion of hydrogen peroxide to water and oxygen.  Other non-
enzymatic antioxidants like glutathione (GSH) and thioredoxin (Trx) play important 
roles in the elimination of ROS (Figure 2) [16].  
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Figure 2. Sources of ROS and its cellular response.  Production of ROS 
within the cell can be the result of endogenous or exogenous sources.  To 
maintain homeostasis in the levels of ROS, cells contain antioxidant 
defense mechanisms. An increase in antioxidants like superoxide 
dismutase (SOD), catalase (CAT), glutathione (GSH) and thioredoxin (Trx) 
help the cells to maintain homeostasis.  When levels of ROS decrease or 
increase, different physiological functions can be affected. 
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Glutathione (GSH) 
GSH is a tripeptide consisting of glutamate, cysteine and glycine.  These amino 
acids are assembled into active GSH through the enzymatic action of γ-
glutamylcysteine synthetase and GSH synthetase [17].  This molecule is the most 
abundant thiol containing peptide within the cells.  Its major function is to work as a 
reducing agent and ROS scavenger.  A reactive sulfhydryl group drives its antioxidant 
function.  In addition to working as an antioxidant, GSH plays different roles within the 
cell including metabolism of xenobiotics, cell-cycle regulation, control of mitochondrial 
mediated cell death, modulation of immune response and regulation of protein function 
and gene expression via thiol-disulfide exchange reactions [17].  Due to its important 
role in cell physiology, alterations in GSH levels have been associated with the 
development of different diseases, including neurodegenerative disorders, diabetes, 
cardiovascular diseases and cancer [18, 19].  
GSH, serving as an electron donor, can reduce disulfide bonds-containing 
proteins to cysteines.  As a ROS scavenger, GSH works by converting reactive 
species such as hydrogen peroxide to less reactive molecules.  In this process, 
glutathione peroxidase (GPX) catalyzes the conversion of GSH to the oxidized 
glutathione disulfide (GSSG).  Subsequently, GSSG can be reduced back to GSH by 
glutathione reductase in a reaction that requires NADPH as an electron donor (Figure 
3) [17].  The ratio of GSH to GSSG within the cell is regularly used as a measurement 
of cellular toxicity [20].  In addition to functioning as an antioxidant, GSH also plays 
important roles in the generation of other antioxidants like vitamin C and E [17].   
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Figure 3.  GSH antioxidant reaction.  Superoxide (O2-) is converted to 
hydrogen peroxide (H2O2) by a reaction catalyzed by superoxide 
dismutase (SOD).  Using reduced glutathione (GSH) as a substrate, 
glutathione peroxidase (GPX) converts H2O2 to water (H2O).  During this 
reaction GSH is oxidized to glutathione disulfide (GSSG).  GSSG can be 
reduced back to GSH by glutathione reductase using NADPH as a 
substrate.  
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Thioredoxin (Trx) 
Trx is another important thiol containing antioxidant, which plays a role in 
maintaining redox homeostasis within the cell.  Human Trx was originally cloned as an 
adult T cell leukemia (ATL)-derived factor; produced by a HTLV-1 transformed T cell 
line ATL-2 cells [21].  Trx is a 12 KDa selenoprotein containing two redox-active 
cysteines and a conserved active site.  The Trx system is primarily composed of two 
isoforms of Trx, which include cytosolic Trx1 and mitochondrial Trx2.  Two other major 
members of this family include Trx reductase-1 and -2 (TrxR-1 & TrxR-2), which are 
localized in the cytosol or the mitochondria respectively [22].  To maintain homeostasis 
Trx-binding protein 2 (TBP-2), also known as Trx-interacting protein (TXNIP), works as 
a negative regulator of Trx.  This molecule binds directly to Trx, resulting in decreased 
antioxidant capacity [23].  Similar to GSH, Trx aids in the removal of hydrogen 
peroxide and plays an important role in reducing disulfide bond-containing proteins.  In 
this process, peroxiredoxin catalyzes the conversion of reduced Trx (Trx-S2) to its 
oxidized form (Trx-(SH)2).  Then Trx-(SH)2 can be reduced back to Trx-S2 by 
thioredoxin reductase (TrxR) using NADPH as an electron donor [22] (Figure 4A).   
In addition to working as an antioxidant, Trx has pleiotropic functions within the 
cell.  Trx has been known to act as a growth factor, activator of transcription factors 
and apoptotic controller [22].  This pleiotropic function is driven by its interaction with 
other proteins like the transcription factor NF-κB and the apoptosis signal-regulating 
kinase 1 (ASK-1) (Figure 4B).  In the case of NF-κB, reduced Trx can bind to NF-κB, 
helping in its translocation to the nucleus and binding to DNA, which results in gene 
expression (Figure 4C) [24, 25].  This binding to the DNA is regulated by the reduction 
of a disulfide bond in cysteine 62 of the p50 subunit of NF-κB [26].  As an apoptotic 
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controller, reduced Trx can bind to ASK-1, which is required for TNF-α-induced 
apoptosis [27, 28]. The binding to ASK-1 results in inhibition of ASK-1 dependent 
apoptosis (Figure 4B).  In the presence of TNF-α or generation of ROS, Trx is oxidized 
resulting in dissociation of ASK-1, subsequently leading to its activation and apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
The balanced production of ROS and antioxidants is important to maintain redox 
homeostasis and for the proper function of the cell.  An imbalance between 
antioxidants and oxidants results in oxidative stress, which can affect cell survival in 
different forms.  Under oxidative stress, elevated levels of ROS can result in damage 
of lipid membranes, proteins and DNA [16].   Alterations in cellular metabolism and 
antioxidants levels have been associated with different human diseases including 
neurodegenerative diseases, cardiovascular disorders and cancer [16].    
Figure 4.  Pleiotropic effect of Trx.  A) Trx works as a ROS 
scavenger by removing hydrogen peroxide (H2O2). This 
reaction is catalyzed by peroxiredoxin. B) Trx also regulates 
apoptosis by binding to apoptosis signaling-regulating kinase-1 
(ASK-1).  C) Reduced Trx can bind directly to NFΚB affecting 
gene expression.  
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In the next section we will discuss the different redox alterations that can result in the 
development of cancer, focusing primarily on ALL.  
 
1.2.2 Redox alterations in leukemia and its implication in cancer therapy 
Several studies have demonstrated that cancer cells, including the cells of 
hematological malignancies, have higher levels of ROS than normal cells [29, 30].  
These elevated levels of ROS have been associated with tumor initiation, promotion 
and maintenance of the cancer cells [16].  The exact mechanisms responsible for the 
redox alterations observed in leukemic cells are not clear.  Several studies suggest 
that elevated levels of ROS in leukemia can be the result of oncogenic activation.  The 
BCR/ABL oncogene, which is expressed in CML and a subtype of ALL, has been 
demonstrated to alter redox homeostasis by increasing the levels of peroxide and 
superoxide [31, 32].  In addition to BCR/ABL, other alterations like overexpression of 
the antiapoptotic protein BCL-2 has been associated with redox control in leukemia.  
BCL-2 can function as an oncogenic signal affecting the production of GSH resulting in 
redox alteration in ALL cells [33, 34].  In this case, inhibition of BCL-2 with the agent 
ABT-737 in ALL cells results in GSH depletion and increase oxidative stress [34].  
Another explanation for the elevated levels of ROS observed in leukemias is the 
hyperactivation of endogenous sources of ROS such as the mitochondrial electron 
chain.  Mutations in mitochondrial DNA have been observed in different leukemias [35, 
36].  These mutations can alter the electron transport chain resulting in oxidative 
stress.  Furthermore, ROS production by complex I of the mitochondrial electron chain 
was reported as a survival factor in ALL patient samples [37].   
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As observed in other cancer cells, leukemia cells appear to have altered 
expression or dysregulation of antioxidant proteins.  This dysregulation can result in 
elevated expression of antioxidants, which allows leukemic cells to readily cope with 
the increased ROS production.  Antioxidants that have been reported to be up-
regulated in ALL include GSH and Trx.  Different studies have compared healthy 
donor samples with leukemia patient samples.  The results demonstrated higher GSH 
levels in CLL, AML and ALL patients compared to healthy individuals [38, 39].  Several 
studies have also associated elevated levels of GSH with resistance to chemotherapy 
in ALL cells [40, 41].  Furthermore, there is a correlation between elevated GSH and 
an increased risk of relapse in pediatric patients with ALL [42].   
Trx dysregulation has also been demonstrated to alter the redox status in 
leukemias.  Trx is upregulated in leukemias resulting in sustained growth and 
decreased apoptosis [43].  Studies in acute leukemia patient samples have found a 
correlation between elevated Trx mRNA expression with relapse and poor prognosis, 
suggesting Trx is a negative prognostic indicator [44].  The activation of Trx pathways 
in acute leukemia seems to be different between leukemia types.  In AML patient 
samples, TBP-2 is overexpressed resulting in decreased Trx activity and elevated 
ROS [45].  In contrast, TBP-2 is lost in ALL and consequent upregulation of Trx is 
observed.  In this study re-expression of TBP-2 resulted in growth inhibition [46].  
On the other hand, dysregulations resulting in decreased levels of antioxidants 
can lead to elevation of ROS levels.  Consequently this elevation in ROS can result in 
proliferation and genomic instability.  SOD, is an antioxidant, which catalyzes the 
conversion of superoxide to hydrogen peroxide and catalase.  Studies have reported 
decreased levels of SOD in lymphocytes from ALL patients when compared to healthy 
donors samples [47, 48].  Another example of decreased levels of antioxidants in 
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leukemia includes catalase.  Catalase is an enzyme involve in the elimination of 
hydrogen peroxide.  ALL cells have lower levels of catalase activity compared to 
normal cells.  These results were associated with an increase in hydrogen peroxide 
and genomic instability [48]. 
These redox alterations in cancer cells have been exploited for the identification 
and development of new specific and selective anticancer treatments. It has been 
hypothesized that if a chemotherapeutic agent has the ability to push ROS levels in 
malignant cells past a particular threshold, cell death will occur [29].  In contrast, this 
increase in ROS will not cause major damage to normal cells due to their low basal 
ROS levels.  Some of the chemotherapeutic agents that have been shown to induce 
oxidative stress mediated apoptosis in leukemia cells include: proteasome inhibitors, 
Bcl-2-targeted agents, kinase inhibitors and HDACi [49, 50].  The following section 
focuses on HDACi as a targeted agent inducing oxidative stress mediated apoptosis.   
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1.3     Histone deacetylase inhibitors (HDACi) 
1.3.1 Rationale for the development of HDACi 
Cancer has traditionally been defined as a genetic disease where genetic 
alterations have been considered as a major cause of carcinogenesis [51].  
Carcinogenesis or development of cancer consists of three major steps: initiation, 
promotion and progression.  During the initiation step, genetic alteration or mutations 
result in the formation of cancer cells.  In the promotion step, the cancer cells are 
clonally expanded and finally in the progression step additional genetic mutations can 
be acquired.   Mutations in oncogenes and tumor suppressor genes may result in 
changes in gene expression, which has been attributed to the development of cancer. 
In the past few years, completion of the human genome sequence has led to 
the study of epigenetics.  Epigenetics is defined as a heritable change in gene 
expression without alterations in the underlying DNA sequence [52].  Several studies 
have demonstrated that as genetic alterations, epigenetic changes in gene expression 
can be involved in the process of carcinogenesis [53].  While many genetic defects, 
such as gene deletions, cannot be reversed, many epigenetic abnormalities in cells 
can be reversed, making epigenetic changes attractive targets for the development of 
new therapies.  Two of the most common epigenetic alterations observed in cancer 
are DNA methylation and post-translational modification of histones.   
DNA methylation is the most studied epigenetic alteration in cancer.  The 
process of DNA methylation involves DNA methyltransferases (DNMTs), which 
transfer methyl groups from S-adenosylmethionine to cytosines that are part of CpG 
dense regions or better known as CpG islands [54].  The methylation of these regions 
is associated with transcriptional repression.  Studies have demonstrated that cancer 
cells exhibit different patterns of DNA methylation in genes involved in important cells 
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functions like cell cycle regulation, DNA repair, and tumor suppression and/or histone 
modification compared to normal cells [55-57].   
The second most studied epigenetic alteration includes the post-translational 
modifications of histones.  Histones are proteins found predominantly within the cell 
nucleus and the major role is to package the DNA to form the nucleosome, which is 
the basic building block of the chromatin. Histone modifications include: methylation, 
acetylation, phosphorylation, ubiquitination and ADP-ribosylation [58].  These 
modifications give the nucleosome a structure where different processes like 
transcription, DNA replication, and DNA repair take place.   
Histone acetylation has been identified as a target for the treatment of cancer.  
The acetylation of histones is a dynamic process, which include two different enzymes: 
the histone acetyltransferases (HATs) and histone deacetylases (HDACs) (Figure 5).  
The HATs are divided into five families, which include the GNAT superfamily, the Myst 
family, p300/CBP, TAFII 250 and nuclear receptors [59].   These enzymes use acetyl-
CoA to add acetyl groups to lysine residues on histone tails.  The amine groups 
present in lysine confer a positive charge to histone tails [60].  This positive charge 
interacts with the negative charge found on the phosphate group of the DNA chain.  
Histone acetylation changes the amine groups to amides, which neutralizes the 
positive charge on the histone tail resulting in decreased ability of histones to bind the 
DNA chain [60].  The decrease interaction of histone with the DNA chain confers a 
more relaxed chromatin structure allowing different transcription factors and molecular 
complexes to interact with the chromatin resulting mainly in gene transcription [61].   
In contrast, the HDACs, which are divided into four classes (Figure 6), remove 
acetyl groups.  The removal of acetyl groups increases the positive charge of histone 
which then can interact with the DNA chain resulting in a more compacted chromatin, 
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which is associated with transcriptional repression [60].  In addition to histones, 
HDACs can acetylate lysine residues on non-histone proteins like transcription factors, 
chaperone proteins and other proteins involved in cell signaling [62].  This acetylation 
in non-histone proteins can interfere with binding, activity or stability of the protein.   
 
 
 
 
 
 
 
Different studies have demonstrated the association of abnormal expression of 
HDAC with cancer [63].  Histone hypoacetylation has been associated with the 
silencing of important genes like tumor suppressor genes and genes involved in cell 
differentiation and apoptosis [64].  Also, loss of acetylation of lysine 16 in histone H4 
has been associated with cancer [65].  Furthermore, studies suggest a possible 
relation between histone modification patterns and poor outcome in different types of 
cancer [56, 66].  As results of all these observations, new therapies that target 
epigenetic changes in cancer have been developed.  One of these emerging new 
therapies includes the histone deacetylase inhibitors (HDACi). 
HDACi are a group of compounds that block the activity of HDACs resulting in 
hyperacetylation of histones or non-histone proteins.  This group of inhibitors includes 
Figure 5.  Chromatin acetylation.  Acetylation of histone tails is driven by 
the homeostasis between histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) enzymes. HATs add acetyl groups to the histone 
tails allowing a more relax chromatin structure. HDACs remove the acetyl 
groups resulting in a more compacted chromatin.   
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natural and synthetic derivates, which are grouped on the basis of chemical structure 
and their ability to inhibit the activity of specific HDACs (Figure 6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These compounds were discovered through different observations where 
treatment with dimethyl sulfoxide (DMSO) and the antibiotic trichostatin A (TSA) 
induced cell differentiation and cell cycle arrest in murine erythroleukemia cells [67, 
68].  More detailed observations demonstrated that TSA targets HDACs resulting in 
their inhibition and consequently histone hyperacetylation [68].  Based on these 
Figure 6.  HDAC enzyme family. HDAC are divided in four classes based 
on their catalytic domain and cellular localization Class I, II a, II b and IV.  
Different HDAC inhibitors have been developed to target specific HDAC.  
Pan-HDAC inhibitors include: vorinostat, Trichostatin A (TSA) and 
panobinostat (LBH589).  Inhibitors selective for class I HDAC include: 
entinostat and depsipeptide. Class I and II a inhibitors include: valproic acid 
(VPA), butyrate and trapoxin.  More specific inhibitors like tubacin inhibit 
specifically HDAC 6, a member of the Class II b. 
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observations different efforts have been directed to develop agents with similar activity 
observed by DMSO and TSA treatments.   Presently, there are approximately six 
classes of HDACi, including short-chain fatty acids, hydroxamic acids, and benzamide 
[69].  The efficacy of HDACi in inhibiting the enzymatic activity of HDACs varies 
between classes (Figure 6). 
Vorinostat, or originally named by its chemical structure as suberoylanilide 
hydroxamic acid (SAHA; Figure 7) is the first HDACi approved by the U.S. Food and 
Drug Administration for treatment of cutaneous T-cell lymphoma.  
 
 
 
 
 
This agent was first identified as an HDACi by Richon et al., where they reported 
that vorinostat inhibited the activity of HDACs 1 and 3 in cancer cells [70].  Subsequent 
studies demonstrated that vorinostat works as a pan-HDAC inhibitor blocking the 
enzymatic activity of class I, II and IV HDAC [71].  In vitro studies have demonstrated 
that vorinostat has different biological effects including cell cycle arrest, cell 
differentiation, induction of apoptosis, angiogenesis inhibition and modulation of 
immune response [71].  In addition to increasing histone acetylation, vorinostat has the 
ability to induce non-histone proteins.  Increased acetylation of different transcription 
factors like p53, E2F and HIF-1α and cytoplasmic proteins like tubulin and HSP90 
have been associated with the mechanism by which this agent induces cell cycle 
arrest and cell death [71].  The anticancer effect of vorinostat has been also tested in 
Figure 7. Chemical structure of vorinostat. Vorinostat or 
SAHS is a hydroxamic acid, which is a pan-HDAC inhibitors.  
www.lclabs.com 
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in vivo models.  In a xenograft model of prostate cancer, administration of 50 mg/kg 
vorinostat resulted in significant suppression of tumor growth when compared to mice 
receiving vehicle alone [72].  In an in vivo model of ALL, vorinostat was administrated 
at different doses including 50, 100 and 150 mg/kg resulting in growth suppression of 
the xenograft tumors [73].    
Entinostat is a novel HDACi, which is currently in clinical trials for the treatment 
of different cancers.  Entinostat, previously known as MS-275, is a benzamide with 
selective inhibition of class I HDAC, specifically HDAC 1, 2 and 3.   
 
 
 
 
 
 
 
Different studies have demonstrated that this agent induces cell cycle arrest, cell 
differentiation and apoptosis in cancer cells [74].  In vitro studies using leukemia cell 
lines and patient samples demonstrated that lower doses of entinostat induced p21-
dependent growth arrest.  In contrast, treatment with higher concentrations of this 
agent induced apoptosis in these samples [75].  This agent also has the ability to 
target leukemic oncogenes like FLT3-ITD.  FLT3-ITD is an oncogene associated with 
acute leukemias.  In a study using FLT3 positive leukemia cells, entinostat induced 
acetylation of HSP90 and ubiquitination of FLT3 resulting in degradation of FLT3 and 
cell death [76].  Another mechanism by which this agent can induce growth arrest is 
Figure 8. Chemical structure of entinostat. Entinostat or MS-275 
is a benzamide which inhibits class-I HDACs.  www.exchemistry.com 
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through the Akt pathway.  Entinostat blocked the Akt signaling in AML cells resulting in 
growth arrest and cell differentiation [77].  In vivo studies using different cancer model, 
including sarcoma and neuroblastoma, demonstrated that administration of entinostat 
inhibited the growth of established tumors [74]. 
In general, the rationale behind the development of HDACi is that these drugs 
will increase acetylation of histones, which may lead to the reactivation of important 
genes involved in cell proliferation, cell differentiation, modulation of the immune 
response and induction of cell death.  Interestingly, several studies have demonstrated 
that HDACi also induce oxidative stress as one of its mechanism of action.  The 
following two sections will discuss the mechanism by which HDACi induce apoptosis 
and oxidative stress.     
 
1.3.2 Induction of apoptosis by HDACi  
In general, HDACi have been demonstrated to induce apoptosis in different 
types of cancer cells, including leukemic lymphocytes and myelocytes [78].  Apoptosis 
is defined as programmed cell death, which is physiological necessary to eliminate 
unwanted cells within an organism [79].  This type of cell death is characterized by 
changes in the cells that include: cell shrinkage, disruption of the mitochondria, DNA 
fragmentation and the appearance of apoptotic bodies.  These apoptotic bodies are 
recognized by phagocytes, which finally engulf and eliminate the dead cell.   
The process that directs all these changes within the cells is very complex and 
organized.  There are two major pathways by which the cells undergo apoptosis: the 
extrinsic pathway (death-receptor pathway) and the intrinsic pathway (mitochondrial 
pathway) [79].  Both of these pathways are driven by different proteases better known 
as caspases (cysteine-directed aspartate specific proteases).  These enzymes 
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recognize and cleave their substrates at tetra-peptide sites that have specific 
sequences.  Caspases are divided into initiators (activator) caspases, effector 
(executioner caspases) depending on their function [79].   
The extrinsic pathway is mainly driven by the initiator caspase-8.  This pathway 
is initially activated by the binding of FasL, TRAIL or TNF-α to death receptors 
localized at the cell membrane.  This binding results in the oligomerization of the death 
receptor and the internal recruitment of the adaptor protein FADD with the caspase-8.  
The complex of FADD and caspase-8 form the death-inducing signaling complex 
(DISC), which initiates the apoptotic process through the cleavage of caspase-8 or -
10.  The activation of caspase-8 or -10 induces the activation of the effector caspases-
3 or -7, which ultimately results in all the biochemical and morphological changes 
associated with apoptosis [79]. 
The intrinsic pathway is regulated by pro-apoptotic and anti-apoptotic proteins.  
Pro-apoptotic proteins like Bax can activate the intrinsic pathway by binding to the 
mitochondrial membrane.  This binding results in mitochondrial membrane 
perturbation and the release of cytochrome c, which then associates with procaspase-
9 and the adaptor protein Apaf-1 to form the apoptosome.  The apoptosome, activates 
the initiator caspase-9 which ultimately cleaves and activates the executors, caspase-
3 or -7 resulting in cell death.  The intrinsic pathway can also be activated by the 
extrinsic pathway.  In this case the pro-apoptotic protein Bid serves like a link between 
the two pathways.  Bid is cleaved and activated by caspase-8 resulting in the fragment 
tBid, which then binds to the mitochondrial membrane resulting in the activation of the 
intrinsic pathway.  Depending on the target cell and the specific HDACi, different 
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studies have demonstrated that HDACi can induce apoptosis in cancer cells by the 
two-apoptotic pathways, the extrinsic and the intrinsic pathway. 
In terms of the extrinsic pathway, in vitro studies using AML cell lines and patient 
blast samples, demonstrated that vorinostat and entinostat induce the gene 
expression of TRAIL by directly activating the TNFSF10 promoter, which consequently 
activates the extrinsic apoptotic pathway by binding to death receptors [80].  However 
this effect was not observed in normal CD34+ cells, which were resistant to HDACi 
induced-apoptosis [80]. Furthermore, in vivo studies validated the previous 
observations, demonstrating that suppressing TRAIL and Fas by siRNA resulted in 
significant reduction in apoptosis after treatment with HDACi [81].  In addition to these 
observations, Guo et al. demonstrated that treatment of ALL cells with the HDACi 
LAQ824 increases the mRNA and protein expression of the death receptors DR5 and 
DR4 [82].  In contrast, studies using lymphoma cells found that knockout of TRAIL or 
inhibition of caspase-8 activation have no effect on the apoptotic induction by LAQ824 
and LBH-589 [83].  These last observations suggest that the activation of the extrinsic 
pathway by HDACi may be cell-type dependent.  Other mechanisms by which HDACi 
can activate the extrinsic pathway can be through the recruitment of FADD and 
activation of caspase-8.  Treatment of TRAIL resistant CLL cells with TSA and 
romidepsin resulted in sensitization of these cells to TRAIL induced apoptosis through 
the recruitment of FADD and caspase-8 into the DISC [84].   
In addition to the extrinsic apoptotic pathway, HDACi have demonstrated to 
induce apoptosis through the intrinsic apoptotic pathway.  These drugs can 
transcriptionally activate BH3-only proteins including Bid, Bad and Bim, which are 
important proteins in the activation of the intrinsic pathway [85-87].   
 24 
Treatment of leukemia patient samples with vorinostat induced the cleavage of 
caspase-8, -9 and -3.  However, the overexpression of Bcl-2 in these cells resulted in 
complete inhibition of vorinostat-induced apoptosis [88].  Further studies using an in 
vivo model of Burkitt’s lymphoma, demonstrated that overexpression of Bcl-2 resulted 
in resistance to HDACi, again validating the importance of the prosurvival Bcl-2 protein 
[89].  Studies have demonstrated that HDACi can also induce the cleavage of Bid 
resulting in disruption of the mitochondrial membrane, release of ROS and cytochrome 
c and ultimately apoptosis in leukemia cells [87]. 
In addition to inducing apoptosis by the up- or down-regulation of apoptotic 
related proteins, several studies have demonstrated that HDACi induces oxidative 
stress in different types of cancer cells [87, 90, 91].  However the mechanisms by 
which HDACi induce oxidative stress is not well understood. These studies suggest a 
possible role of redox regulation in the efficacy of HDACi alone and in combination 
with other anticancer agents.  As presented in previous sections, redox alterations in 
cancer cells can be used as a strategy to treat cancer.  Understanding how agents like 
HDACi can alter the redox status in cancer cells is of critical importance for the 
development of more effective agents, in this case HDACi.  Furthermore 
understanding of these mechanisms can help to anticipate possible drug resistance 
and better design of clinical trials that include combinations of HDACi with other 
anticancer agents.  The following section will discuss the literature that support the 
mechanisms by which different HDACi induce oxidative stress. 
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1.3.3 Induction of oxidative stress by HDACi 
The mechanisms by which HDACi induce oxidative stress is not well understood.  
Two possible mechanisms have been reported.  The first one reported vorinostat to 
induce apoptosis by the expression of Bid, a pro-apoptotic protein, which resulted in 
disruption of the mitochondria and consequent production of ROS (Figure 4A) [69].  
The second mechanism involved the antioxidant thioredoxin (Trx).  Studies have 
shown vorinostat to inhibit Trx as a mechanism by which oxidative stress may occur 
[92].  An explanation for this Trx inhibition is that vorinostat increased the expression 
of thioredoxin-binding protein (TBP-2), which binds and inactivates Trx (Figure 4B).  
Furthermore, additional studies showed that non-transformed cells displayed higher 
levels of Trx compared to transformed cells.  Non-transformed cells with higher levels 
of Trx were more resistant against HDACi.  Otherwise, transformed cells with lower 
levels of Trx were more sensitive to vorinostat and entinostat [93].    
Interestingly, post-translational modifications of Trx, like glutathionylation [94], 
have been shown to affect its activity. A recent study reports Trx to be acetylated by 
vorinostat [62], however it is unknown if Trx acetylation affects its activity.  Trx 
acetylation and consequent Trx inhibition may work as a novel mechanism of how 
HDACi induce oxidative stress in cancer cells and will be tested in this dissertation.  
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Figure 9.  Proposed mechanism of ROS induction by HDACi.  A) HDACi can 
induce the expression of BID, which associates with the mitochondrial membrane 
resulting in release of ROS.  B) HDACi can induce the expression of TBP-2, 
which binds to Trx inhibiting its activity resulting in ROS accumulation [2]. 
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1.3.4 HDACi in the clinic 
As presented in previous sections, HDACi have gained widespread attention due 
to its anticancer activity in preclinical studies.  In addition, multiple clinical trials using 
HDACi as a single agent and in combination with other chemotherapies have yielded 
promising results.  This section will discuss some of the clinical trials using HDACi.  
Vorinostat was the first HDACi showing positive results in clinical trials.  This 
agent was approved for the treatment of cutaneous T-cell lymphoma.  During phase I 
and II trials, vorinostat was well tolerated and 30% of the patients enrolled in the trial 
responded positively to the treatment [95].  These trials resulted in the approval of 
vorinostat for the treatment of this type of cancer.  Recently, clinical trials using 
vorinostat have evaluated its efficacy in different types of leukemias.  A phase I trial of 
vorinostat in AML patients demonstrated effective inhibition of HDAC activity in blood 
and bone marrow samples [96].  A second phase I trial evaluated the maximum 
tolerated dose (MTD) and the side effects of vorinostat in pediatric leukemia patients 
[97].  The MTD reported in these patients was 230 mg/m2/d administrated orally and 
the side effects included nausea, loss of appetite and fatigue.  Overall, this trial 
concluded that the pharmacokinetics of vorinostat in children was similar to that 
observed in adult patients [97].  Gojo et al. reported a phase I trial using entinostat in 
adults with refractory and relapsed acute leukemias.  In this study, entinostat 
effectively inhibited HDAC activity, induced p21 expression, histone acetylation and 
caspase-3 activation in bone marrow cells [98].  In summary, these studies 
demonstrate HDACi to be promising for the treatment of hematological malignancies. 
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In addition to hematological malignancies, several clinical trials have been 
conducted to test these agents in patients with glioblastoma, ovarian, breast, 
colorectal and lung cancer [99-101].  In contrast to patients with hematological 
malignancies, these trials resulted in moderate or no effect.  Possible explanation for 
the efficacy differences between liquid and solid tumors include the inability to achive 
appropriate doses of HDACi and consistent acetylation of target proteins.  In clinical 
trials vorinostat’s half-life is relatively short, 91.6 to 127 minutes administrated orally 
and 34.7 to 42.4 minutes administrated intravenously [102, 103].  These data suggest 
that continuous administration of this agent may be necessary to achieve clinical 
response.  
While vorinostat has been approved as a single agent for the treatment of 
cancer, several preclinical and clinical studies have demonstrated that HDACi work 
better in combination with other anticancer agents [104].  HDACi have been combined 
with conventional cytotoxic therapies like DNA-damaging and targeted therapies like 
proteasome inhibitors and hypomethylating agents [105-107]. These combinations 
produced enhanced apoptosis in different malignant cell lines.  Several clinical trials 
are presently being conducted using HDACi in combination with other 
chemotherapies; however, the mechanism of action of these combinatorial treatments 
is not well understood. 
As mentioned before, HDACi have been shown to induce oxidative stress in 
different cancer cells.  Knowing that cancer cells have higher levels of ROS compared 
to normal cells, this difference can be used as a therapeutic strategy to treat cancer. 
Combining HDACi with agents that cause further oxidative stress might enhance the 
efficacy of HDACi for the treatment of cancer.   
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Different studies combining HDACi with other chemotherapies have shown to induce 
oxidative stress, however the mechanism by which these combination induce oxidative 
stress is not very well understood.  Rosato RR, et al. reported that the HDACi LAQ-
824 in combination with fludarabine synergistically increased ROS levels in ALL cells.  
This increase in ROS resulted in DNA damage [108].  Oxidative stress is also a 
marker for the synergy observed between entinostat and the chemotherapeutic agent 
5-azacytidine in AML and ALL cells [109].  PEITC is another compound that induce 
oxidative stress and has been combined with HDACi.  In this study, depletion of GSH 
by PEITC increases sensitivity to vorinostat in leukemia cells [110].  Furthermore, the 
combination of HDACi with PEITC also induced ROS accumulation and apoptosis in a 
vorinostat-resistant cell line via activation of the NADPH oxidase.  Induction of ROS by 
this combination allows for the translocation of the transcription factor Nrf2 to the 
nucleus, stimulating transcription of genes involved in the GSH system [110].   
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1.4     Adaphostin as a ROS generating agent  
Adaphostin has been identified as a potential anticancer agent to treat acute 
leukemias such as ALL and AML. This molecule is a second-generation tyrphostin 
kinase inhibitor, which mimics tyrosine binding to kinases [111].  While this agent was 
developed as a BCR/ABL kinase inhibitor, subsequent studies have demonstrated that 
adaphostin’s antileukemic activity is not selective for the presence of Bcr/Abl kinase 
[112].  Importantly, adaphostin demonstrates selectivity for leukemia cells as 
compared to normal lymphocytes [113].  Subsequent studies have been devoted to 
understanding the mechanism of action of this drug. 
 
 
 
 
 
 
 
Mechanistic studies have demonstrated that adaphostin increases levels of 
intracellular ROS by the depletion of GSH, resulting in DNA damage and induction of 
apoptosis in leukemia cells [113].  More detailed investigations have explained the 
induction of oxidative stress by adaphostin.  Le, S.B. et al reported that the increase in 
ROS in cells treated with adaphostin is the result of an accumulation in the 
mitochondria, where adaphostin binds to complex III, inhibiting electron transport 
[114].  Moreover, transcriptional and proteomic analyses of adaphostin-treated cells 
demonstrated an upregulation of oxidative stress-related genes [115, 116].   
Figure 10. Chemical structure of adaphostin. Adaphostin is a 
second-generation tyrphostin kinase inhibitor.  www.trc-canada.com 
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Hose, C. et al. performed a transcriptional profile in three different leukemia cells lines 
(Jurkat, K562 and HL60) treated with 1 and 10 µM of adaphostin for 2 to 6 hours.  The 
results demonstrated that adaphostin cytotoxicity in these cells is caused by the 
release of free iron resulting in redox alteration and cell death [115].  In a second 
study, proteomic analyses performed in myeloid leukemia cells treated with increasing 
concentrations of adaphostin resulted in upregulation of oxidative stress related 
proteins such as heat shock proteins, glutathione s-transferase, and superoxide 
dismutase [116].    Furthermore, studies in glioblastoma cells treated with adaphostin 
indicate that the antioxidant heme oxygenase-1 is upregulated [117]. 
Combinatory studies also have demonstrated the importance of ROS in the 
cytotoxic effect of adaphostin.  A panel of leukemia cells was treated with adaphostin 
in combination with the proteasome inhibitor bortezomib, resulting in synergistic 
induction of apoptosis.  This synergy was associated to elevated levels of ROS, 
downregulation of the Raf/MEK/ERK pathway and JNK activation.  All these events 
were attenuated when cells were treated with the antioxidant NAC, demonstrating that 
oxidative stress plays an important role in the synergistic mechanism [118].  This 
combination was also tested in BCR/ABL positive cells resistant to imatinib resulting in 
synergistic induction of apoptosis in which potentiation of ROS was observed.  Again, 
NAC blocked the synergistic effect implicating oxidative stress as a mechanism by 
which this combination overcomes imatinib resistance [118].  Taken together, these 
observations indicate that adaphostin is a redox-modulatory agent.  
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Two different studies of adaphostin’s effect in vivo have been reported.  One 
study showed that adaphostin increased survival in an orthotopic glioblastoma mouse 
model [119].  The second study, a report on the pharmacokinetics of adaphostin, 
showed that adaphostin was stable in human plasma [120].  Collectively, this data 
points to adaphostin as a good candidate to study in combination with HDACi.  
 
1.5     Study Rationale, Hypothesis and Specific Aims 
Despite advances in the treatment of pediatric leukemia, 20% of children die 
due to relapsed or refractory disease. Furthermore, survivors have an increased risk of 
death compared to age matched cohorts due to late effects of their therapy. 
Identification and development of new therapeutic strategies with specific and 
selective antileukemia activity are of utmost importance for these patients. Histone 
deacetylase inhibitors (HDACi), have shown to be effective in the treatment of 
hematological malignancies. The major accepted mechanism of action for these drugs 
is through hyperacetylation of histones. Interestingly, several studies have indicated 
that HDACi cause oxidative stress, which contributes to the cytotoxicity of these drugs 
[87]. Combining agents that cause further oxidative stress might enhance the efficacy 
of HDACi for the treatment of leukemia. The tyrphostin inhibitor adaphostin is one such 
agent. Adaphostin was originally identified as a tyrosine kinase inhibitor, but 
subsequent studies defined oxidative stress as its primary mechanism of action. 
Furthermore, adaphostin demonstrates selectivity for leukemia cells as compared to 
normal lymphocytes [113]. The present study investigates the efficacy and the redox 
mechanism of HDACi in combination with adaphostin in leukemia models. 
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The hypothesis for this study is that HDACi in combination with adaphostin 
will synergize, causing oxidative stress and cell death through the activation of 
the apoptotic mitochondrial pathway.   
To test this hypothesis the following specific aims were conducted: 
• Specific Aim 1:  To determine the mechanism by which HDACi and adaphostin 
synergize to induce apoptosis.  
• Specific Aim 2:  To determine how ROS is generated by the combination and 
its role in the induction of apoptosis.  
• Specific Aim 3:  To determine how specific HDACi alter the oxidative 
environment to promote cell death. 
Understanding the mechanism involved in the synergy between HDACi and 
adaphostin will advance scientific knowledge of how the action of HDACi could be 
augmented in leukemia models.  Moreover, this information could be used for the 
development of effective clinical trials combining HDACi with other anticancer agents. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1      Cell lines   
Jurkat and Molt-4 cells, representative of human T-acute lymphocytic leukemia 
(T-ALL) and I9.2 (caspase-8 deficient Jurkat cells) were acquired from American Type 
Culture Collection (ATCC; Manassas, VA). All cell lines were validated by short 
tandem repeats (STR) DNA fingerprinting by the MD Anderson characterized cell line 
core (CCSG) laboratory.  All cells were grown in a humidified incubator with 5% CO2 at 
37o C.  Jurkat and Molt-4 were cultured in RPMI 1640 with 10% (Jurkat) or 20% (Molt-
4) (v/v) heat-inactivation fetal bovine serum (FBS; Hyclone, Logan, UT), 2 mM L-
glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin (Sigma St. Louis, MO).  
I9.2 cells were cultured in RPMI 1640 with HEPES (N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic), sodium pyruvate and L-glutamine (ATCC; Manassas, VA) 
supplemented with 15% FBS and 100 U/mL penicillin, and 100 g/mL streptomycin 
(Sigma St. Louis, MO). 
 
2.2      Chemicals and antibodies   
Adaphostin was provided by the NCI/NIH Developmental Therapeutics Program 
(Bethesda, MD). Vorinostat was purchased from Cayman Chemicals (Ann Arbor, MI) 
and entinostat was provided by Syndax (Waltham, MA). Propidium iodide (PI), N-
Acetyl-L-cysteine (NAC), thioredoxin reductase from rat liver, NADPH and insulin from 
bovine pancreas were purchased from Sigma (St. Louis, MO).  Dye for the detection of 
intracellular superoxide (dihydroethium - HE) was purchased from Invitrogen (Grand 
Island, NY). Tetramethylrhodamine ethyl ester (TMRE) was purchased from Molecular 
Probes (Eugene, OR). Caspase-3 substrate, DEVD-amc and the caspase inhibitors 
zVAD-fmk, DEVD-fmk, LEHD-fmk and IETD-fmk were purchased from Enzo Life 
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Sciences (Farmingdale, NY). Antibodies were purchased for polyclonal anti-acetyl-
histone H3 and anti-histone H3 (Abcam, Inc., Cambridge, MA), monoclonal anti-
thioredoxin (BD Biosciences Pharmigen, San Diego, CA) and anti-acetylated lysine 
(Cell Signaling, Danvers, MA).  
 
2.3      DNA fragmentation and synergy analysis  
Sub-diploid population was measured as an indicator of apoptosis using 
propidium iodide (PI) staining followed by flow cytometric analysis.  After 24 h of 
incubation with desired treatment, cells were centrifuged, washed with PBS and 
suspended in 500 µL of PI solution (50 g/mL PI, 0.1 % Triton X-100, and 0.1% 
sodium citrate in PBS) for a minimum of 3 h. Samples were assessed by flow 
cytometry on the FL-3 channel (FACSCalibur, Becton, Dickinson, Franklin Lakes NJ). 
CellQuest software (BD Bioscience, Franklin Lakes NJ) was used for analysis of the 
data.  After three different experiments, synergy was calculated using isobologram 
analysis based on the Chou and Talalay method [121] with Calcusyn software (Biosoft, 
Ferguson, MO).   
 
2.4      Detection of changes in mitochondrial membrane potential 
Changes in mitochondrial membrane potential were measured using 
tetramethylrhodamine ethyl ester (TMRE) staining.  TMRE is a cell permeable dye with 
positive charge, which is reduced by the interaction with active positively charged 
mitochondria.  Increase in reduced TMRE is indicative of changes in mitochondrial 
membrane potential.  After treatment with synergistic concentrations, cells were 
centrifuged, washed with PBS, and incubated with 25 nM TMRE in 10 mM HEPES, 
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150 mM NaCl, 5 mM KCl, 1 mM MgCl, and 1.8 mM CaCl, pH 7.4 in a volume of 1 mL 
for 30 min at 37°C in the dark. After 30 min, cells were washed in PBS and 
fluorescence intensity was analyzed by flow cytometry on the FL-2 channel and 
analyzed by CellQuest software.   
 
2.5      Detection of intracellular superoxide   
The intracellular superoxide level was measured using the cell-permeable 
dihydroethidium (HE) dye followed by flow cytometry analysis. Briefly, cells were 
centrifuged and suspended in 1 mL of PBS containing 330 nM HE. The samples were 
incubated for 30 min in the dark at 37o C.  Cells were centrifuged and washed with 
PBS and re-suspended in 500 µl of PBS. Fluorescence intensity was assessed by flow 
cytometer on the FL-3 channel and analyzed by CellQuest software.  
 
2.6      Caspase-3-like activity assay  
After treatment with the synergistic concentrations, cells were centrifuged, 
washed, then suspended in 150 µl PBS and lysed by freezing and thawing once on dry 
ice. Triplicates of 50 µl of lysate were loaded in a 96-well plate and 150µl of 50 M 
DEVD-amc in DEVD buffer (10% sucrose, 0.001% IGEPAL, 0.1% CHAPS, 5 mM 
HEPES, pH 7.25) were added to each well. The release of fluorescence (amc) 
generated from the cleavage of DEVD-amc was measured using a spectrofluorometer 
(SpectraMax Gemini EM, Molecular Devices, Sunnyvale, CA) with an excitation of 355 
nm and emission of 460 nm. 
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2.7      Acid extraction of histones  
Purification of histones was performed as described previously [122]. Briefly, 
after drug treatment, cells were harvested and nuclei were isolated by lysis of cells in a 
hypotonic buffer containing 10 mM Tris-HCl, pH 8.0, 1 mM KCl, 1.5 mM MgCl2, 1 mM 
DTT.  Protease and phosphatase inhibitors at a final concentration of 1 mM were 
added immediately prior to lysis. Lysates were rotated for 30 min at 4°C, and then 
centrifuged for 10 min at 10,000 rpm at 4°C.  Supernatant was removed and isolated 
nuclei were suspended in 400 µl of 0.4 N H2SO4 and rotated for 30 min or overnight at 
4°C.  Nuclei lysates were centrifuged for 10 min at 12,500 rpm at 4°C to remove the 
nuclear debris. Supernatant was transferred to a new eppendorf tube and 132 µl of 
trichloroacetic acid (TCA) was added and incubated on ice for 30 min, then centrifuged 
for 10 min at 12,500 rpm at 4°C.  Supernatant was removed and the histone pellet was 
washed with ice-cold acetone and centrifuged for 5 min at 12,500 rpm at 4°C.  Finally 
the acetone was removed and histone pellets were dissolved in 100 µl of sterile water. 
 
2.8      Immunoprecipitation   
After treatment, cells were resuspended in lysis buffer (1% Triton X-100, 150 
mM NaCl, 5 mM EDTA, 20 mM sodium phosphate, pH 7.4).  Aliquots of protein lysates 
(1000 µg) were immunoprecipitated overnight with 1 µg/mL of Trx antibody.  Protein G 
agarose beads were added to each sample and rotated for a minimum of 2 h, then 
washed with lysis buffer and centrifuged three times.   Samples were loaded onto a 
15% sodium dodecyl sulfate (SDS)-polyacrylamide gel, transferred to nitrocellulose 
membrane, and blocked for 1 h with 5% nonfat dry milk in Tris-Buffered Saline Tween-
20 (TBS-T) (0.05% Tween-20). Membranes were probed overnight at 4oC with 1:1000 
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dilution of primary antibody (acetylated-lysine) in 5% milk in TBS-T. The bound 
antibodies were detected using enhanced chemiluminescence, ECL plus Western 
blotting detection system (Amersham Bioscience, UK limited, Little Chalfont 
Buckinghamshire, England). 
 
2.9      Quantification of cellular glutathione (GSH) levels  
After 24 h of treatment, cells were harvested and equal numbers of cells were 
aliquoted to new tubes and 50 µM of monochlorobimane (mBCL) was added to each 
sample, except for the unstained control.  mBCL is a cell permeable probe, which 
react with the thiol groups in GSH resulting in release of a fluorescent signal.  Cells 
were incubated with the mBCL for 15 minutes at 37°C.  After incubation, the reaction 
was stopped by adding trichloroacetic acid to a final concentration of 5%. Samples 
were collected and an equal volume of methylene chloride was added, followed by 
centrifugation at 3500 RPM for 2 minutes. After centrifugation, 200 µl from the 
aqueous phase was collected in a well of a white opaque 96 well plate. Fluorescence 
was measured using a microplate reader (Spectra Gemini EM, Molecular Devices, Inc. 
Sunnyvale CA) with excitation 398 nm and emission of 488 nm. GSH level was 
calculated using a standard curve with increasing GSH concentration that was 
prepared in parallel with the samples.  
 
2.10    Thioredoxin Activity   
Trx activity was determined using a spectrophotometric end-point insulin assay, 
where insulin is used as a substrate to measure the thiol formation in the reaction 
[123].  Briefly, after treatment with the synergistic concentrations, cells were 
centrifuged, washed with PBS and homogenized in cold buffer (50 mM potassium 
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phosphate, pH 7.4, containing 1 mM EDTA) followed by three cycles of freezing and 
thaws.  Thirty µg of sample protein were incubated with 85 mM HEPES, 0.3 mM 
insulin, 660 µM NADPH, 3 mM EDTA and 0.1 unit of Trx reductase (TrxR) at 37°C for 
60 min. After incubation, the reaction was stopped by adding 500 µl of 6 M guanidine 
hydrochloride with 4 mg/mL of 5,5′-dithio-bis (2-nitrobenzioic acid). Absorbance at 412 
nm was measured using a SpectraMax Gemini EM spectrophotometer. For each 
sample, a blank containing all reagents, except TrxR, was used, and absorbance of 
the blank was subtracted from that of the sample with TrxR. 
 
2.11    Oxidative stress and antioxidant defense PCR array   
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Valencia, 
MA).  The concentration and quality of the RNA were measured using a NanoDrop 
ND-1000 Spectrophotometer (Thermo Scientific Inc., Walthaman, MA).  For each 
sample, 0.5 µg of RNA was used to synthesize cDNA using the RT2 First Strand Kit 
(Qiagen, Valencia, MA).  Real-time PCR was performed according to the 
manufacturer’s protocol conditions (Qiagen, Valencia, MA). 
 
2.12 In vivo experiments 
Female NOD/SCID, NOD-SCID-IL-2gnull and NOD-Cg-Rag1 mice purchased 
from the National Cancer Institute (Bethesda, MD) were used.  All animals used for in 
vivo experiments were housed in standard cages, at three to four mice per cage and 
provided with food and water.  Animal experiments were performed in accordance with 
the MD Anderson Institutional Animal Care and Use Committee and approved by the 
American Association for Laboratory Animal Science (AALAS).  Mice were injected 
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intravenously (IV) with 1x105 Molt-4 cells (representative of T-ALL).  One week after 
cell injection, mice bearing leukemia cells were divided into four groups (3 mice per 
each group).  Each mouse was injected intraperitoneally (IP) with vehicle, single drugs 
alone or drugs in combination.  Dosing was done thrice weekly.  To determine 
treatment efficacy, we conducted complete blood cell counts using approximately 25 µl 
of mouse blood on a weekly basis.  Lymphocytes were isolated adding 1 mL of ACK 
(Ammoniun-Chloride-Potassium) lysing buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA) to blood.  Then samples were mixed followed by centrifugation at 12,000 RPM 
for 3 minutes.  After centrifugation, supernatant was carefully aspirated and cell pellet 
was suspended in 50 µl of PBS.  Isolated lymphocytes from mice were stained using 
10 µl APC anti-human CD45 antibody (Biolegend Inc. San Diego, CA) in 50 µl of PBS 
containing cells, followed by flow cytometery and analysis using CellQuest software. 
 
2.13    Statistical analysis   
For each condition, at least three experiments were performed, and the results 
are presented as the mean ± standard deviation (SD).  Statistical differences between 
conditions were analyzed using independent, two-tailed t-tests (Microsoft Excel 
software, Redmond, WA).  A p-value < 0.05 was considered to be statistically 
significant.  To determine synergy, Calcusyn software (Biosoft, Ferguson, MO) was 
used to calculate combination index (CI) values with isobologram analysis using the 
Chou and Talalay method [121].  A CI value less than 1.0 indicates synergy, equal to 
1.0 indicates an additive effect and more than 1.0 represents an antagonist interaction.  
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CHAPTER 3: RESULTS 
3.1    HDACi (vorinostat and entinostat) synergize with adaphostin to induce 
DNA fragmentation in ALL cells.   
Previous studies have demonstrated that HDACi work better in combination 
than as a single agent in different types of cancer including hematological 
malignancies.  In addition, data suggests that one mechanism of action for HDACi is 
through the induction of oxidative stress.  To test if combining HDACi with a ROS 
generating agent would augment HDACi efficacy, we treated two different types of ALL 
cell lines with HDACi and adaphostin (a ROS generating agent).  Jurkat and Molt-4 
cells were treated with a range of HDACi (vorinostat or entinostat) and adaphostin 
concentrations (100 nM – 2.5 µM), incubated for 24 h and DNA fragmentation was 
determined by flow cytometry.  Figure 11 shows an increase in DNA fragmentation 
when Jurkat and Molt-4 cells were treated with increasing concentrations of the single 
agents.  DNA fragmentation was significantly enhanced in Jurkat cells when treated 
with increased concentrations of adaphostin (0.5 and 0.75 µM) with 0.75 µM of 
vorinostat (63.5% and 71.8%, respectively; p < 0.05) or adaphostin (0.5, 0.6 and 0.75 
µM) with 2.5 µM of entinostat (68.3%, 78.7 and 83.6%, respectively; p < 0.05).  In 
Molt-4 cells, a significant increase in DNA fragmentation was observed when 1.5 or 
2.5 µM adaphostin was combined with 1.5 µM vorinostat (70.5% and 78.3%, 
respectively; p < 0.05) or 2.5 µM adaphostin with 2.5 µM of entinostat (76.3%; p < 
0.05).   
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Figure 11. Combination of HDACi (vorinostat or entinostat) with 
adaphostin induces DNA fragmentation. 5 x 105 Jurkat cells (left 
panel) and Molt-4 cells (right panel) were treated with increasing 
concentrations (0.1-2.5 µM) of adaphostin (Ada), vorinostat (Vori), 
entinostat (Enti) or the combination of Ada-Vori or Ada-Enti for 24 h. 
(Drug concentration for Jurkat cells were 0.25, 0.5 and 0.75 µM Ada or 
Vori; 1, 1.5 and 2.5 µM Enti.  For Molt-4 0.75, 1.5 and 2.5 µM Ada; 0.5, 
0.75 and 1.5 µM Vori; 0.75, 1.5 and 2.5 µM Enti).  DNA fragmentation 
(% Subdiploid) was assessed by PI staining following flow cytometry. 
Error bars represent the means ± S.D. of three independent 
experiments. *p < 0.05 as compared with either ada, vori or enti 
treatment alone. 
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Synergy analysis using the Chou and Talalay method [121], demonstrates that 
adaphostin synergizes with both vorinostat or entinostat in Jurkat and Molt-4 cells.  A 
combination index (CI) value less than 1.0 indicates synergism whereas a CI value 
equal to 1.0 or more than 1.0 indicates an additive or antagonist interaction 
respectively.  Representations of different synergistic combinations are presented in 
Figure 12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 12. HDACi (vorinostat or entinostat), synergize with 
adaphostin to induce DNA fragmentation.  Synergy was calculated 
using isobologram analysis.  A combination index (CI) value < 1.0 
indicates synergism. Tables display some of the synergistic 
combinations in Jurkat and Molt-4 as indicated by the CI values. 
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   To test if the combination of HDACi and adaphostin has any toxic effects in 
normal cells, peripheral blood mononuclear cells (PBMC) from healthy donors were 
isolated and treated with the synergistic combinations of 0.5 µM adaphostin plus 0.5 
µM vorinostat or 0.75 µM adaphostin plus 2.5 µM entinostat.  Cells were harvested 
after 24 h of incubation and cell viability was measured by trypan blue exclusion.  
Figure 13 shows that neither combination affected the viability of PBMC (Figure 13).  
In contrast, Jurkat cells treated with both combinations show a decrease in cell viability 
demonstrating specificity for leukemic cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The combination of HDACi and adaphostin do not affect 
the cell viability of healthy peripheral blood mononuclear cells 
(PBMC). 5 x 105 PBMC or Jurkat cells were treated with 0.75 µM Ada, 
0.5 µM Vori, 2.5 µM Enti and the synergistic combinations of 0.5 µM Ada 
plus 0.5 µM Vori or 0.75 µM Ada plus 2.5 µM Enti.  After 24 h treatment, 
cell viability was measured by trypan blue exclusion. Error bars represent 
the means ± S.D. of three independent experiments. 
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To elucidate the mechanism of synergy, the subsequent experiments were 
performed in Jurkat cells with specific synergistic drug concentrations.  The synergistic 
concentrations were selected based on the CI values (Figure 12).  We decided to 
select two combinations that resulted in the low CI value of 0.6.  These combinations 
were 0.5 µM of adaphostin in combination with 0.5 µM of vorinostat and 0.75 µM of 
adaphostin with 2.5 µM entinostat.   
Since HDACi alone are known to induce acetylation of histones, we tested 
whether the synergistic combinations have any further effect on the acetylation of 
histones.  Jurkat cells were treated with the synergistic combinations of adaphostin 
plus vorinostat or adaphostin plus entinostat and harvested at 24 h.  Acid extraction of 
histones was performed and levels of total and acetylated histone H3 were measured 
by Western blot.  As expected, increases in acetylation of histone H3 were observed in 
cells treated with either HDACi (vorinostat or entinostat).  However, no further changes 
in acetylation were observed with either of the synergistic combinations (Figure 14). 
 
 
 
 
 
 
 
 
 
Figure 14. Synergistic combinations do not affect the 
acetylation of histone H3 induced by HDACi. 5 x 106 Jurkat 
cells were treated with the synergistic combinations of 0.5 µM 
Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti.  After 24 
h of incubation cells were harvested and acid extraction of 
histones was performed. Acetylated histone H3 and total 
histone H3 were measured by Western blot. 
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3.2    Induction of DNA fragmentation by HDACi and adaphostin is caspase-
dependent.   
Previous results demonstrate that the combination of HDACi and vorinostat 
synergize to induce DNA fragmentation in ALL cells.  Since DNA fragmentation is a 
hallmark of apoptosis, we next investigated if a caspase-dependent apoptotic pathway 
was activated.  In order to test if caspase-3 is activated and specifically at what time it 
is activated, we measured caspase-3-like activity in cells treated with the drug 
combinations at different time points.  Jurkat cells were treated with the synergistic 
combinations of adaphostin plus vorinostat or adaphostin plus entinostat and 
harvested at different time points (2, 4, 8, 12, 16 and 24 h).  Caspase-3-like activity 
was measured using DEVD-amc as a substrate. Cleavage of this substrate by 
caspase-3 liberates amc, creating a fluorescent signal, which was read on a 
spectrofluorometer.  Figure 15 shows that both combinations increased caspase-3-like 
activity in a time dependent manner. Significant changes were observed at 12 h when 
compared to control (p-value < 0.05).  
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To validate the previous results and to determine which specific apoptotic 
pathway is activated, cells were pre-treated with either 20 µM zVAD-fmk (pan caspase 
inhibitor), 25 µM IETD-fmk (caspase-8 inhibitor), 25 µM LEHD-fmk (caspase-9 
inhibitor) or 25 µM DEVD-fmk (caspase-3 inhibitor) for 30 min and then treated with 
the synergistic concentrations of HDACi and adaphostin for 24 h.  After 24 h, the cells 
were stained with PI and DNA fragmentation was measured by flow cytometry.  As 
shown in Figure 16, apoptotic DNA fragmentation induced by the combinations was 
significantly reduced when caspase-8, -9 or -3 activity was blocked (p-value < 0.05).  
Comparing the fold changes in DNA fragmentation using each inhibitor, the caspase-9 
inhibitor confers the stronger effect (7 fold change for ada-vori or 11 fold change for 
ada-enti) when compared to caspase-8 (3 fold change for ada-vori or 2 fold change for 
Figure 15. The combination of HDACi and adaphostin induce 
caspase-3 activation in a time dependent manner.  2 x 106 Jurkat 
cells were treated with the synergistic combinations of 0.5 µM Ada 
and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. Caspase-3 activity 
was assessed by measuring the fluorescent intensity released from 
the cleavage of the fluorogenic substrate DEVD-amc at different time 
points (2 – 24 h). Error bars represent the means ± S.D. of two 
independent experiments. *p < 0.05 as compared with control or 
either agent alone.  
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ada-enti) or caspase-3 (3 fold change for ada-vori or 5 fold change for ada-enti) 
inhibitors.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Induction of DNA fragmentation by HDACi and 
adaphostin synergy is caspase dependent.  5 x 105 Jurkat 
cells were pre-treated with either 20 µM pan-caspase, 25 µM 
caspase-3, caspase-8 or caspase-9 inhibitors for 30 min. After 
pre-treatment, the samples were treated with 0.5 µM Ada and 
0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti for 24 h and dyed 
with PI. DNA fragmentation was assessed by flow cytometer. 
Error bars represent the means ± S.D. of three independent 
experiments.  *p < 0.05 as compared with no inhibitor.  
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 To better understand the role of caspase-8 in the induction of DNA 
fragmentation by the synergistic combinations, Jurkat variants that were caspase-8 
deficient (I9.2 cells) were used.  Parental Jurkat and I9.2 cells were treated with both 
synergistic combinations for 24 h.  DNA fragmentation was measured by flow 
cytometry using PI staining.  In both combinations, cells that lacked caspase-8 showed 
a moderate decrease in DNA fragmentation when compared to parental Jurkat cells 
(Figure 17 A-B).  These data suggest that caspase-8 is not the principal caspase 
involved in the synergy between HDACi and adaphostin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Caspase-8 is not required for the induction of DNA 
fragmentation by the combination of HDACi and adaphostin. 
5 x 105 cells, either I9.2 (caspase-8 deficient) or parental Jurkat 
cells were treated with the synergistic combinations of 0.5 µM Ada 
and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti for 24 h.  DNA 
fragmentation was measured by PI staining in cells treated with 
the synergistic concentration of A) Ada-Vori and B) Ada-Enti. Error 
bars represent the means ± S.D. of three independent 
experiments.  
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3.3   The combination of HDACi and adaphostin disrupts the mitochondrial 
membrane potential and potentiates superoxide levels.   
Previous data generated using caspase inhibitors and caspase-8 deficient cells 
suggest that caspase-9 mediates the induction of apoptosis in cells treated with the 
combination of HDACi and adaphostin.  Since caspase-9 can be activated by both 
apoptotic pathways (extrinsic and intrinsic), we tested if these drug combinations have 
any effect on the mitochondrial membrane potential.  To determine if mitochondrial 
membrane potential is affected and specifically at what time this event occurs, Jurkat 
cells were treated with both combinations and harvested at different time points (2, 4, 
8, 12, 16 and 24 h).  Changes in mitochondrial membrane potential were measured by 
flow cytometry using TMRE staining.  Significant loss of membrane potential was 
detected at 12 h and sustained through 24 h in both combinations (Figure 18 A-B).   
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Combination of HDACi and adaphostin disrupts 
mitochondrial membrane potential starting at 12 h.  5 x 105 
Jurkat cells were treated with the synergistic combinations of 0.5 
µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. After 
treatment changes in mitochondrial membrane potential was 
measured by TMRE staining in A) Ada-Vori or B) Ada-Enti 
combinations at different time points (2-24 h).  *p < 0.05 as 
compared with control.  
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To elucidate whether the loss of mitochondrial membrane potential precedes or 
follows caspase activation, cells were pre-treated with the pan-caspase inhibitor ZVAD 
followed by treatment with the synergistic concentrations.  After 24 h, cells were 
harvested and mitochondrial membrane potential was measured.  Figure 19 shows 
that ZVAD blocked the loss of membrane potential caused by both combinations. 
These results suggest that caspase activation is downstream of the changes in 
mitochondrial membrane potential. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Caspase activation is downstream of loss of 
mitochondrial membrane potential. 5 x 105 Jurkat cells were 
pre-treated with 20 µM pan-caspase inhibitor for 30 min. After 
pre-treatment cells were treated with the synergistic 
combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada 
and 2.5 µM Enti.  After 24 h mitochondrial membrane potential 
was measured by TMRE staining. Error bars represent the 
means ± S.D. of three independent experiments.  
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Increased endogenous levels of ROS can promote mitochondrial membrane 
permeabilization resulting in the release of cytochrome c and activation of caspase-9. 
Since decreased mitochondrial membrane potential has been shown to promote an 
environment of oxidative stress, we sought to determine whether there was an 
increase in superoxide levels and, if so, at what specific time point these are 
generated. Cells were treated with the combinations and harvested at different time 
points (2, 4, 8, 12, 16 and 24 h) and superoxide levels were measured using HE 
staining.  Results show that both combinations potentiate superoxide levels more than 
the single agents.  Significant increases were observed at 16 h and continued 
increasing through 24 h (Figure 20 A-B).  Based on the time course experiments, 
these results place the induction of oxidative stress downstream of the initial loss of 
mitochondrial membrane potential that started at 12 h. 
 
 
 
 
 
 
 
 
 
Figure 20. HDACi and adaphostin potentiate superoxide levels in a 
time dependent manner. 5 x 105 Jurkat cells were treated with the 
synergistic combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada 
and 2.5 µM Enti. Superoxide levels were measured by HE staining in 
cells treated with the synergistic concentrations of A) Ada-Vori and B) 
Ada-Enti at different time points (2-24 h). Error bars represent the means 
± S.D. of three independent experiments.  *p < 0.05 as compared with 
control.  
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3.4  NAC blocks DNA fragmentation in cells treated with adaphostin and 
vorinostat, but not in cells treated with adaphostin and entinostat.  
 Previous results suggest that oxidative stress might play an important role in the 
mechanism of synergy between HDACi (vorinostat and entinostat) and adaphostin.  In 
order to elucidate if ROS contributes to cell death, we used NAC as an antioxidant.  
Cells were pre-treated with 24 mM NAC for 30 min. Then cells were treated with the 
drug combinations.  After 24 h of treatment superoxide levels, changes in the 
mitochondrial membrane potential, DNA fragmentation and caspase-3 activity were 
measured as previously described.  As expected, NAC decreased the levels of 
superoxide in both combinations, demonstrating that NAC is blocking oxidative stress 
(Figure 21A).  In addition, NAC was able to reverse the loss of mitochondrial 
membrane potential in both combinations, suggesting that production of oxidative 
stress precedes the loss of mitochondrial membrane potential (Figure 21B).  Finally, to 
investigate the role of superoxide production in cell death, we measured DNA 
fragmentation and caspase-3 activity in cells pre-treated with NAC and then with the 
drug combinations.  DNA fragmentation was decreased by NAC in cells treated with 
adaphostin plus vorinostat, but not in cells treated with adaphostin plus entinostat 
(Figure 21C).  These results were confirmed when caspase-3 activation was 
measured in cells pre-treated with NAC followed by the drug combinations (Figure 
21D).  All together, these results suggest that at the synergistic concentrations, the 
combination of adaphostin plus vorinostat might have a different mechanism of 
inducing oxidative stress mediated-apoptosis compared to the combination of 
adaphostin plus entinostat. 
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Figure 21. Superoxide levels precede the loss of mitochondrial 
membrane potential and NAC blocks cell death in cells treated 
with Ada-Vori but not Ada-Enti. Jurkat cells were pretreated with 24 
mM NAC for 30 min, then treated with the synergistic combinations of 
0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti.  After 24 
h treatment, 5 x 105 cells were harvested to measure A) Superoxide 
levels, B) Mitochondrial membrane potential, C) DNA fragmentation and 
2 x 106 cells were harvested to measure D) Caspase-3-like activity. 
Error bars represent the means ± S.D. of three independent 
experiments. *p < 0.05 as compared with no NAC.  
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3.5    Glutathione (GSH) & thioredoxin (Trx) are not affected by the synergistic 
combination of adaphostin and HDACi.   
In order to elucidate the main differences between these two combinations we 
first assessed the involvement of GSH in the mechanism of synergy.   GSH were 
measured in cells treated with the drug combinations.  After 24 h of treatment, cells 
were harvested and GSH levels were measured using monochlorobromane as a 
substrate, which react with the thiol groups in GSH resulting in release of a fluorescent 
signal.  Results show a two-fold decrease in GSH levels in cells treated with 
adaphostin and entinostat, and one-fold decrease in cells treated with adaphostin and 
vorinostat (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Glutathione (GSH) levels in cells treated with 
HDACi and adaphostin. 1 x 106 Jurkat cells were treated with 
the synergistic combinations of 0.5 µM Ada and 0.5 µM Vori or 
0.75 µM Ada and 2.5 µM Enti.  After 24 h treatment, GSH levels 
were measured using monochlorobimane as a substrate. Error 
bars represent the means ± S.D. of three independent 
experiments. 
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Since NAC not only alters the levels of GSH, but any cysteine-containing 
molecule, and to better elucidate the role of GSH in this mechanism, we used 
glutathione ethyl ester (GSHee) to directly address a role for GSH.  GSHee is a 
soluble molecule, which enters in the cell and undergoes hydrolysis by intracellular 
esterases to be converted to GSH.  Therefore, treatment with GSHee is commonly 
used to increase levels of GSH within the cells.   
As expected, increases in GSH levels were observed in cells pre-treated with 
GSHee (Figure 23A).  However GSHee did not block the previously observed loss of 
mitochondrial membrane potential or DNA fragmentation (Figure 23B-C).  These 
results suggest that changes in GSH levels are not the main mechanism of action for 
the generation of oxidative stress in the present model. 
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Figure 23. GSHee increases the levels of GSH but does not 
block the loss of mitochondrial membrane potential or cell 
death in cells treated with HDACi-Adaphostin. Jurkat cells were 
pre-treated with 1 mM GSHee for 30 min and then treated with the 
synergistic combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM 
Ada and 2.5 µM Enti.  After 24 h treatment, 1 x 106 cells were 
harvested to measure A) GSH levels; and 5 x 105 cells were 
harvested to measure B) mitochondrial membrane potential and C) 
DNA fragmentation were measured as described previously. Error 
bars represent the means ± S.D. of three independent experiments.  
*p < 0.05 as compared with no GSHee.  
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Thioredoxin (Trx) is another cellular antioxidant and its activity has been 
demonstrated to be affected by HDACi.  Vorinostat was found to decrease Trx activity 
by the upregulation of thioredoxin binding protein 2 (TBP-2) [92].  Furthermore, recent 
studies have shown that HDACi can acetylate Trx [62].  However, whether this 
acetylation affects Trx activity remains unknown.  We decided to investigate if 
acetylation of Trx plays an important role in the synergy between adaphostin and 
HDACi.  First, we tested if the combination of HDACi and adaphostin induces Trx 
acetylation.  Figure 18A shows that acetylation of Trx is induced in cells treated with 
higher concentrations of vorinostat (5 µM) but not at lower concentrations (0.5 µM 
vorinostat).  However, Trx acetylation was observed in cells treated with 2.5 µM 
entinostat and this acetylation was further increased by the combination of 0.75 µM 
adaphostin and 2.5 µM entinostat (Figure 24A).  In order to elucidate if the synergistic 
combinations affect Trx activity, we measured Trx activity in cells treated with either 
agent alone or in combination.  No changes in Trx activity were observed after 
treatment with either of the combinations (Figure 24B). 
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Figure 24. The combination of HDACi and adaphostin increases 
the acetylation of Trx but does not affect Trx activity. Jurkat cells 
were treated with the synergistic combinations of 0.5 µM Ada and 0.5 
µM Vori or 0.75 µM Ada and 2.5 µM Enti.  After 24 h of incubation 20 x 
106 cells were harvested for the immunoprecipitation and 5 x 106 cells 
were harvested to measure Trx activity. A) Immunoprecipitation of Trx 
was performed and blotted for acetylated Trx. B) Trx activity was 
measured using a spectrophotometric end-point insulin assay. Error 
bars represent the means ± S.D. of three independent experiments. 
 
 60 
3.6  HDACi and adaphostin combinations induce differential regulation of 
oxidative stress related genes.   
Previous results demonstrated that NAC blocked the loss of mitochondrial 
potential and ROS levels, suggesting that oxidative stress plays an important role in 
the synergy between HDACi with adaphostin.  However, NAC blocked DNA 
fragmentation in cells treated with adaphostin plus vorinostat but not in cells treated 
with adaphostin plus entinostat.  To elucidate these differences we investigated the 
role of GSH and Trx.  Results demonstrated that GSH and Trx are not major players in 
these differences.  To better understand what factors are involved in the differences 
between the two combinations, we examined the expression of different genes 
involved in oxidative stress and antioxidant defense.  Since we observed changes in 
superoxide levels starting at 16 h, we hypothesized that gene changes start earlier.  
For that reason, we decided to examine the changes in gene expression at 8 h.  RNA 
was extracted from cells treated with the synergistic combinations for 8 h. cDNA was 
synthesized and a RT2 profile PCR array for genes involved in oxidative stress and 
antioxidant defense was performed.  Gene regulation was compared between cells not 
treated (control) and cells treated with either combination (Ada-Vori or Ada-Enti).  
Then these results were compared between each combination.  We selected the 
genes with the major fold changes in gene regulation induced by Ada-Vori compared 
to Ada-Enti (Table 1). This data shows that genes involved in oxidative stress were 
differentially regulated between Ada-Vori and Ada-Enti combinations.  In cells treated 
with Ada-Enti compared to Ada-Vori, there was up-regulation of aldehyde oxidase 1, 
glutathione peroxidase-2, lactoperoxidase, eosinophil peroxidase 2 and scavenger 
receptor class A.  In cells treated with Ada-Vori compared to Ada-Enti, there were up-
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regulations of glutathione peroxidase 6, peroxiredoxin 6 and down-regulation of 
myeloperoxidase and angiopoietin-like 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Genes involved in oxidative stress are differentially 
regulated between Ada-Vori and Ada-Enti combinations. 5 x 106 
Jurkat cells were treated with the synergistic combinations of   0.5 
µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. After 8 h 
cells were harvested and RT2 profile PCR array for genes involved 
in oxidative stress and antioxidant defense was performed.  
Numbers in red represent a gene up-regulation, numbers in blue 
represent a gene down-regulation and number in black represent no 
change. 
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3.7 In vivo efficacy of HDACi in combination with adaphostin. 
 Previous results demonstrate that two different HDACi synergize with 
adaphostin to induce oxidative stress mediated-apoptosis in vitro. To test if this 
combination works in vivo, we used an orthotopic mouse model.  Since the U.S. Food 
and Drug Administration has not yet approved entinostat, we decided to use vorinostat 
for the in vivo experiments.  Figure 25 shows the experimental design.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Schematic diagram of in vivo experimental design. 
NOD/SCID mice were injected intravenously with leukemia cells and one 
week after cell injection, treatment started.  Drugs were administrated the 
same days thrice weekly.  Leukemia burden was monitored weekly by 
measuring CD34+ cells present in the blood.  
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Twelve NOD-SCID-IL-2gnull mice were injected intravenously (IV) with 1x105 
Molt-4 cells (representative of T-ALL).  One week after cell injection, mice bearing 
leukemia cells were divided into four groups (3 mice per group).  We selected the 
administration routes and doses based on published data [124, 125].  Each mouse 
was injected intraperitoneally (IP) with vehicle, drugs alone or in combination.  Group 1 
was injected with vehicle (DMSO).  Group 2 was injected with 125 mg/kg [124] 
vorinostat.  Group 3 was injected with 50 mg/kg adaphostin [125].  Group 4 was 
injected with the drug combination (vorinostat and adaphostin).  Drug dosing was done 
on the same days thrice weekly.  To determine treatment efficacy we conducted 
complete blood cell counts using approximately 25 µl of mouse blood on a weekly 
basis.  Lymphocytes were isolated using ACK lysing buffer.  Isolated lymphocytes 
were stained using a fluorescence conjugated antibody (APC anti-human CD45) 
followed by flow cytometric analysis. 
After the start of drug administration, the mice injected with 50 mg/kg of 
adaphostin died unexpectedly on day 11.  We observed leukemic cell engraftment at 
week 3.  One mouse from the group treated with vorinostat died on day 29 and the 
rest of the mice died around day 30-33 (Figure 26). 
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Mice treated with 50 mg/kg of adaphostin died during week 1, suggesting 
adaphostin toxicity.  To find a less toxic dosage, we performed a second pilot by using 
NOD-SCID mice, decreasing the drug dosages and changing the treatment schedule.  
On this occasion we treated mice with lower doses of each drug daily instead of thrice 
a week.  Mice were IP injected with 25 mg/kg adaphostin, 50 mg/kg vorinostat or the 
combination of vorinostat and adaphostin.  After the second week of treatment, we 
observed abnormal growth in the abdominal area of mice treated with adaphostin and 
the combination.  Two mice, one control treated with vehicle and one treated with 
adaphostin, were sacrificed and necropsies were performed.   
Figure 26. Molt-4 cells engraftment started at week 3. Twelve 
NOD-SCID-IL-2gnull mice were injected intravenous with 1x105 
Molt-4 cells. After one week of cell injection, 3 mice per group were 
treated thrice weekly with vehicle, 50 mg/kg adaphostin, 125 mg/kg 
vorinostat or the combination of adaphostin and vorinostat. 
Leukemia burden was monitored by bleeding and isolated 
lymphocytes from mouse were stained with anti-human CD45 and 
measured by flow cytometry.  Each bar represents the average of 3 
mice per group or treatment.  No bars are presented in the group 
treated with adaphostin because mice died during week 1. 
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Necropsies demonstrated gastrointestinal (GI) toxicity in mice treated with adaphostin 
(Figure 27).  After these findings, we decided to decrease the dose of adaphostin from 
25 mg/kg to 12.5 mg/kg.   
 
 
 
 
 
 
 
 
 
 
 
 
At week four we did not observe cell engraftment and we injected 5 x 105 Molt-4 
cells into each of the remaining mice.  We did not observe any cell engraftment at 
week 6 (Figure 28) and mice treated with adaphostin and the combination started to 
show GI toxicity again at week eight.  The treatment was stopped at week nine.  
 
 
 
 
 
Figure 27. GI toxicity in mice treated with adaphostin. Necropsy 
of mouse treated with either vehicle (DMSO) or 25 mg/kg 
adaphostin showed an increase in the size of the GI track in mouse 
treated with adaphostin.  In contrast mouse treated with vehicle 
showed normal GI track.  
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Since we observed GI toxicity in mice treated with adaphostin, we decided to 
perform toxicity tests to find the appropriate adaphostin dose and treatment schedule.  
As presented in table 2, six mice were treated with different doses and schedules.  At 
week two, one mouse treated with 12.5 mg/kg adaphostin presented with sign of a 
tumor in the left leg.  We performed a necropsy and we did not find any signs of GI 
toxicity or leukemia burden.  The remaining mice were treated with their respective 
doses for a total of five weeks.  After five weeks, no sign of GI toxicity was observed in 
any of the mice.  
 
 
 
Figure 28. Molt-4 cell engraftment in NOD-SCID mice. NOD-SCID 
mice were injected intravenously with 1x105 Molt-4 cells. After one 
week, mice were treated for five days weekly with vehicle, 25 mg/kg 
adaphostin, 50 mg/kg vorinostat or the combination of adaphostin and 
vorinostat. Leukemia burden was monitored by bleeding and isolated 
lymphocytes from mice were stained with anti-human CD45 and 
measured by flow cytometry.  Each bar represents the average of 3 
mice per group or treatment. 
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Based on the toxicity test, we decide to perform a third pilot study.  On this 
occasion, NOD-Cg-Rag1 mice were injected with 1 x 106 Molt-4 cells per mouse.  After 
seven days mice were treated with vehicle, 50 mg/kg of vorinostat for 5 days/week, 
and/or 8 mg/kg of adaphostin for 3 day/week.  After five weeks of treatment we did not 
observe GI toxicity, but we didn’t see cell engraftment (Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
Table 2. Adaphostin doses and schedule administration.  Mice were 
injected IP with different doses of adaphostin using different schedules.  
After five weeks of treatment, mice were sacrificed and necropsy was 
performed.  
 
Figure 29. Molt-4 cell engraftment in NOD-Cg-Rag1 mice. NOD-Cg-
Rag1 mice were injected intravenously with 1x106 Molt-4 cells. After one 
week, mice were treated with vehicle (5 days/week), 8 mg/kg adaphostin 
(3 days/week), 50 mg/kg vorinostat (5 days/week) or the combination of 
adaphostin and vorinostat.  Leukemia burden was monitored by bleeding 
and isolated lymphocytes from mouse were stained with anti-human 
CD45 and measured by flow cytometry.  Each bar represents the 
average of 3 mice per group or treatment. 
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CHAPTER 4: DISCUSSION 
The main objective of this project is to understand how oxidative stress inducing 
agents might enhance the efficacy of HDACi for the treatment of ALL.  For the first 
time, the ROS generating agent adaphostin was used in combination with two different 
HDACi (vorinostat and entinostat) in ALL cell lines.  DNA fragmentation and 
combination index values demonstrated that HDACi, vorinostat and entinostat, 
synergize with adaphostin to induce apoptosis in ALL cells.  Furthermore, the 
synergistic concentrations do not affect PBMC from healthy donors, demonstrating 
that this effect is selective for ALL cells.  This synergy is mainly driven by the activation 
of the intrinsic apoptotic pathway, where time course analyses showed that 
perturbation of the mitochondrial membrane potential is the earliest event observed.  
Following this event, increasing levels of superoxide, caspase activation and ultimately 
cell death were observed.   
 
Synergistic apoptosis induction by HDACi and adaphostin.  
The observation that HDACi synergizes with adaphostin resulting in apoptosis 
is consistent with other studies combining HDACi with different drugs like 
topoisomerase inhibitors [126], nucleoside analogs [108], hypomethylating agents 
[127], proteasome inhibitors [50, 128] and tyrosine kinase inhibitors [129].  However, 
the mechanism by which these combinations induce apoptosis differs between 
combinations.  These observations can be possibly explained by the pleiotropic effects 
of HDACi and the specificity of the cancer cell type.  Furthermore, the mechanism of 
action of the agent with which the HDACi is combined also plays a role in which 
apoptotic mechanisms are activated.   
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 In the present study, results of experiments using different caspase inhibitors 
(pan-caspase, caspase-8, -9, and -3 inhibitors) confirmed that the synergy observed 
between HDACi and adaphostin is through the induction of apoptosis.  Both caspase-8 
and -9 chemical inhibitors reduced DNA fragmentation in cells treated with the 
synergistic concentrations of HDACi and adaphostin (Figure 16).  However, the 
caspase-9 inhibitor exerted a strong inhibition of cell death in both combinations. In 
addition, we found that both combinations induced loss of the mitochondrial membrane 
potential (Figure 18).  Together, these results suggest that the main mechanism by 
which HDACi and adaphostin induce apoptosis is through the intrinsic pathway.  
These observations are consistent with other studies where HDACi has activated the 
intrinsic pathway in different types of cancer cells [130].   
Zhang, et al. examined the effect of the HDACi, suberic bishydroxamate 
(SBHA), which is a derivate of vorinostat, in a panel of human melanoma cell lines.  
They found that HDACi activated the intrinsic apoptotic pathway. This activation was 
attributed to the down-regulation of antiapoptotic proteins XIAP, Bcl-XL and Mcl-1 and 
the up-regulation of proapoptotic genes like Bax, Bak and Bim.  These changes 
resulted in mitochondrial disruption and consequent activation of caspase-3 [130].  In 
contrast to this study, we did not observe changes in the protein levels of XIAP 
(Appendix).  This discrepancy can be explained by the use of the combination 
vorinostat or entinostat plus adaphostin instead of SBHA alone.  Also the cancer type, 
since they used melanoma cells instead of leukemia cells might play an important role.   
Other studies using vorinostat have also shown activation of the intrinsic 
apoptotic pathway by up-regulating Bim in lymphomas [89].  In addition, cleavage of 
Bid, perturbation of the mitochondria and release of cytochrome c also has been 
reported by others [87, 89].  In a similar way, entinostat induced the activation of the 
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intrinsic pathway in lymphoma cells by the down-regulation of Bcl-2 and Bcl-xL 
proteins.  The combination of entinostat with two different Bcl-2 inhibitors significantly 
enhanced this effect [131].  Furthermore, different studies have demonstrated that 
overexpression of the Bcl-2 family of proteins can block the cell death induced by 
HDACi [85, 132].  
HDACi can activate not only the intrinsic apoptotic pathway but also the 
extrinsic apoptotic pathway.  Nebbioso et al. reported that vorinostat and entinostat 
induced the expression of TRAIL in AML cells and in AML blast cells isolated from 
patients.  The overexpression observed was the result of the activation of the promoter 
TNFSF10 [80].  Other studies have demonstrated that HDACi require caspase-8 to 
exert their cytotoxic effect, also can enhance the extrinsic pathway signal by 
increasing death receptors (DRs) or ligand expression [82, 133, 134]. 
We observed a decrease in DNA fragmentation with the caspase-8 inhibitor. In 
addition, it is well known that activation of caspase-8 can subsequently activate the 
intrinsic pathway by the cleavage of Bid.  We investigated the role of the extrinsic 
pathway in the synergy of HDACi and adaphostin.  Pre-treatment with a pan-caspase 
inhibitor followed by the synergistic concentrations demonstrated that caspase 
activation is downstream of changes in the mitochondrial membrane potential (Figure 
19).  Furthermore, data with I9.2 cells, a caspase-8 deficient cell, demonstrate no 
significant decreases in DNA fragmentation when compared to their parental Jurkat 
cells (Figure 17). Together, this data validates that HDACi in combination with 
adaphostin induce cell death in ALL through the intrinsic apoptotic pathway. 
As mentioned before, the mechanism by which the agent combined with HDACi 
functions also plays a role in how the cell death is induced.  The present study used 
adaphostin that has been shown to induce apoptosis in different hematological 
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malignancies and solid tumors [112, 117].  Adaphostin is a tyrosine kinase inhibitor 
originally developed to target BCR/ABL positive cells.  Svingen et al. demonstrated 
that adaphostin activates the apoptotic intrinsic pathway in K562 and blast CML 
patient samples.  Treatment with adaphostin resulted in release of cytochrome c from 
the mitochondrial, and activation of caspases-9 and -3 [135].  Transfecting cells with a 
cDNA encoging dominant-negative caspase-9 inhibited the apoptotic changes 
observed.  However, these changes were not inhibited with the transfection of cells 
with cDNA encoding dominant-negative FADD or with treatment of the blocking 
antibody anti-Fas [135].  These results demonstrated that adaphostin induce apoptosis 
via the intrinsic pathway.  These observations are consistent with our results 
demonstrating the involvement of the intrinsic apoptotic pathway in the synergistic cell 
death induced by adaphostin and HDACi.  Other studies support these results not only 
in BCR/ABL positive cells but also in BCR/ABL negative cells [113].   
More detailed studies demonstrated that the main mechanism by which 
adaphostin induces cell death in different cancer cells is through the production of 
ROS [113].  These increases in ROS have been shown to be the direct effect of 
adaphostin binding to complex III of the mitochondrial electron transport chain [114].  
In addition, studies have demonstrated that adaphostin has the ability to alter different 
antioxidant levels like GSH, glutathione S-transferase, superoxide dismutase and 
heme oxygenase-1 [113, 116, 117].  Consistent with these results, we demonstrated 
that ALL cells treated with low concentrations of adaphostin alone resulted in a loss of 
mitochondrial membrane potential starting at eight hours (Figure 18).  Increased levels 
of superoxide and caspase activation at sixteen hours followed this event (Figure 15, 
20).  Furthermore, the combination of adaphostin with two different HDACi (vorinostat 
and entinostat) resulted in potentiation of all these events. 
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Interestingly, several studies have demonstrated that different HDACi have the 
potential to induce oxidative stress in different cancer cells.  These observations 
directed us to investigate the role of oxidative stress in the synergy between HDACi 
and adaphostin, which is discussed in the next section. 
 
Induction of oxidative stress by the combination of HDACi and adaphostin. 
 In order to investigate if oxidative stress plays a role in HDACi and adaphostin 
synergy, we measured superoxide levels in cells treated with the synergistic 
combinations.  Time course experiments demonstrated that both combinations 
potentiated superoxide levels starting at sixteen hours of treatment (Figure 20).  This 
data is consistent with observations by others, where adaphostin and different HDACi 
used as a single agent induce oxidative stress in cancer cells.  Ruefli et al. 
demonstrated that lymphoblastic leukemia cells treated with HDACi resulted in up-
regulation of the pro-apoptotic gene Bid.  The expression of Bid resulted in disruption 
of the mitochondria and an increase in ROS levels [87].    Similarly, Rosato et al. 
demonstrated that HDACi induce ROS in leukemia cells resulting in DNA damage and 
cell death [75, 108].  Furthermore, several studies combining HDACi with other 
chemotherapeutic agents have demonstrated a significant increase in oxidative stress 
in different cancer cells [108-110].  
 Previous studies have shown that adaphostin depletes GSH levels resulting in 
accumulation of ROS and subsequent cell death in leukemic cells [113].  Similarly, 
You et al. demonstrated that the HDACi trichostatin A induced depletion of GSH, 
which resulted in an increase in superoxide levels and cell death in HeLa cells [136].  
More recently, studies combining the agent PEITC, which has been shown to deplete 
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GSH, with vorinostat also resulted in ROS accumulation and induction of apoptosis in 
a vorinostat resistant cell line [137].   
In order to elucidate if GSH plays an important role in the mechanism by which 
HDACi and adaphostin induce oxidative stress, we measured the levels of GSH in 
cells treated with the synergistic concentrations of HDACi and adaphostin.  Unlike 
previous studies, adaphostin alone did not affect GSH levels (Figure 22).  This 
discrepancy can be explained by the concentration used in the previous study, where 
cells were treated with 10 µM of adaphostin for three hours.  In contrast in the present 
study, the highest concentration used was 750 nM for twenty-four hours.  In addition, 
the previous study used CML cells compared to the present study where we used ALL 
cells, in which the drug can act by different mechanisms.  Similarly to adaphostin, 
vorinostat alone failed to decrease GSH levels.  However, the combination of 
vorinostat plus adaphostin slightly decreased GSH levels when compared to vorinostat 
alone.  Interestingly, entinostat alone decreased the GSH levels and was further 
decreased by the combination with adaphostin.  However, the decrease in GSH failed 
to achieve statistical significance in all treatments (Figure 20).  This differences 
between vorinostat and entinostat can be explained by the concentration used, being 
0.5 µM for vorinostat and 2.5 µM for entinotat.  In addition the specificity of the HDACi 
can be involved in this differences.  Future studies can explore the relation of HDACi 
treatment concentrations and the inhibition of specific HDAC with the regulation of 
GSH as antioxidant.     
Additional experiments using pre-treatment of GSHee followed by the 
synergistic combinations of HDACi and adaphostin, demonstrated increases in GSH 
levels (Figure 23).  However, these increases failed to block the mitochondrial 
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disruption and the DNA fragmentation observed by the treatment of both combinations 
(Figure 23).  Based on these results, we can speculate that GSH is not a major player 
in the induction of oxidative stress by the combination of HDACi and adaphostin.  
However, we cannot discard the possibility of GSH depletion working in conjunction 
with other sources of ROS. 
To further investigate the role of oxidative stress in the synergy of HDACi and 
adaphostin, we used the antioxidant NAC.  Pre-treatment with NAC followed by the 
synergistic combinations of HDACi and adaphostin resulted in a significant inhibition of 
superoxide levels, demonstrating that NAC is working by blocking ROS (Figure 21 A).  
In addition, DNA fragmentation was significantly inhibited in cells pre-treated with NAC 
and followed by the treatment of vorinostat plus adaphostin (Figure 21 C).  
Interestingly, this inhibition was not observed in cells treated with entinostat plus 
adaphostin (Figure 21 C).  These results were consistent with data assessing 
caspase-3 activation in cells pre-treated with NAC followed by the drug combination 
(Figure 21 D).  An explanation for these results might be that induction of ROS plays 
an important role in the combination of vorinostat and adaphostin but not in the 
combination of entinostat and adaphostin.  However, pre-treatment with NAC 
decreased superoxide levels and reversed the loss of mitochondrial potential in both 
combinations (Figure 21 A-B). Together, the data generated using NAC, suggest that 
vorinostat and entinostat in combination with adaphostin might have a different 
mechanism by which induce oxidative stress mediated-apoptosis.   
Another mechanism by which HDACi might induce oxidative stress has been 
linked to their ability to affect the antioxidant Trx.  In this case bladder, prostate and 
breast cancer cells treated with vorinostat resulted in an up-regulation of thioredoxin 
binding protein (TBP-2), which has been demonstrated to bind to the antioxidant Trx 
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and inhibit its activity [92].  Furthermore, Ungerstedt and colleagues demonstrated that 
multiple myeloma and SV-40 transformed cells treated with vorinostat or entinostat 
resulted in ROS-dependent apoptosis.  However, normal human lung and breast 
fibroblast cells treated with HDACi resulted in elevated levels of Trx [93].  These 
elevations in Trx were correlated to HDACi resistance in normal cells. siRNA towards 
Trx sensitized normal cells to HDACi [93].  More recently in vivo studies demonstrated 
that vorinostat can change the oxidation state of Trx toward a more oxidized state, 
which correlated with decreases in enzymatic activity [138].  These studies 
demonstrated that Trx plays a role in the ROS induction by HDACi. 
We tested the possibility of Trx to be involved in the synergy between HDACi 
and adaphostin.  Contrary to previous studies we found that the synergistic 
combinations did not affect TBP-2 mRNA levels (Appendix).  We cannot discard the 
role of Trx in the combination of HDACi and adaphostin, since this combination can 
affect Trx using a different mechanism other than via TBP-2.  Recent data 
demonstrate that HDACi induce acetylation of Trx [62].  However, if the acetylation of 
Trx affects its activity is not known.  To test this possibility, we measured Trx 
acetylation in cells treated with HDACi and adaphostin.  Interestingly, in our model, 
entinostat induced Trx acetylation and this acetylation was further increased with the 
combination of entinostat and adaphostin.  However this level of Trx acetylation was 
not observed in cells treated with vorinostat and adaphostin (Figure 24).  Control 
samples treated with higher concentrations of vorinostat (5 µM) resulted in acetylation 
of Trx.  This observation demonstrated that one of the differences in Trx acetylation 
induced by vorinostat plus adaphostin or entinostat plus adaphostin is the 
concentrations used in each combination.  The low concentration of 0.5 µM vorinostat 
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used in combination with adaphostin did not result in Trx acetylation.  In contrast, 2.5 
µM entinostat used in combination with adaphostin resulted in increased Trx 
acetylation.  In order to test if Trx acetylation can be linked to its enzymatic inhibition, 
we measured Trx activity in cells treated with the synergistic combinations.  We found 
that the combination of adaphostin with HDACi did not affect Trx activity (Figure 24).  
Together this data suggests that Trx is not a major source for the induction of ROS by 
HDACi and adaphostin combinations.  However, these experiments were performed 
looking at Trx1.  Trx has three different isoforms, Trx-1, Trx-2 and Trx-3.  Trx-1 and 
Trx-2 work mainly as antioxidants.  Trx-1 works mainly in the cytosol, where as Trx-2 is 
more directed to the mitochondria [22].  Future studies need to be directed to 
specifically study Trx-2.  This will help to elucidate if Trx-2 plays a role in this 
combination.  Furthermore, additional studies may reveal if different HDACi have 
better affinity for one of the Trx isoforms, which has not been studied yet.  
In order to better elucidate the possible sources of ROS and to understand the 
differences between both combinations, we performed a gene array examining the 
expression of different human genes involved in oxidative stress.  Results 
demonstrated a differential regulation of genes induced by the combination of 
adaphostin-entinostat and adapostin-vorinostat combinations (Table 1).  Differences 
between the combination of vorinostat plus adaphostin and entinostat plus adaphostin 
were analyzed.  Some genes differently affected by one combination versus the 
second combination include aldehyde oxidase 1, peroxiredoxin-6, metallothionein, 
angiopoietin-like 7 and glutathione peroxidase-6.   
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Aldehyde oxidase 1 (AOX1) is one of the genes that can be linked to a possible 
mechanism by which the combination of entinostat plus adaphostin differs from the 
combination of vorinostat plus adaphostin.  AOX1 is member of the molybdenum 
hydroxylase family, which also includes xanthine oxireductase [139, 140].  Its major 
function is to catalize the oxidative hydroxylation of different substrates including: 
nitrogen-containing heterocyclic compounds, aliphatic and aromatic aldehydes.  Its 
actual physiological substrate is unclear but recent data support its involvement in the 
metabolism of certain drugs and the detoxification of xenobiotics [139, 140].  
In addition to catalize the oxidative hydroxylation, AOX1 also can function as an 
oxidase transferring electrons to oxygen resulting in the production of superoxide and 
hydrogen peroxide [139, 140].  Our array data demonstrates that AOX1 is 5.6 fold 
upregulated in cells treated with the combination of entinostat plus adaphostin.  In 
contrast no changes were observed in cells treated with vorinostat plus adaphostin.  
Since AOX1 has been associated with the production of superoxide this suggests a 
possible mechanism by which entinostat plus adaphostin induces superoxide.  To the 
present and to our understanding there is no data showing the effect of NAC in the 
production of ROS by AOX1.  It will be interesting to test the effect of NAC in AOX1.  
AOX1 can be a possible mechanism in which NAC do not affect its action explaining 
the differences in inhibition of DNA fragmentation observed only in the combination of 
vorinostat plus adaphostin and not in entinostat plus adaphostin.  Presently there is no 
a direct correlation between expression of AOX1 and cancer.  However as mentioned 
before, studies has implicate this enzyme with the metabolism of different drugs.  
Some of these drugs include tamoxifen, methortrexate and 6-mercaptopurine [139].  
Studies suggest that AOX1 compete with cytochrome P450, which is a phase I 
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enzyme involved in the metabolism of different drugs and xenobiotics [140].  These 
observations support the involvement of AOX1 in the metabolism of drugs. 
Recent data published by Maeda and colleagues demonstrated that AOX1 
gene is regulated by Nrf2 which binds to the ARE element located in the 5’-upstream 
region of the AOX1 gene resulting in its expression.  This was observed upon the 
exposure to electrophilic agents [141].  Interestingly, Wang et al. reported Nrf2 
activation by HDACi resulting in neuroprotection [142].  It will be interesting to study 
the relation of HDACi, Nrf2 and AOX1 in the combination of entinostat plus 
adaphostin. 
 
Efficacy of HDACi and adaphostin in vivo studies 
Several in vivo studies have demonstrated the efficacy of vorinostat in 
combination with other chemotherapies for the treatment of different types of cancer 
[143-145].  These studies use different doses and schedules, ranging from 50 mg/kg 
daily to 200 mg/kg daily.  These differences can be explained by the use of different 
types of cancer xenografts.  In addition, the route of administration in these studies 
vary with intraperitoneal injections being the most commonly used.  Using a transgenic 
mouse model of acute promyelocytic leukemia, He, et al. demonstrated that daily 
administration for four weeks of 50 mg/kg vorinotat in combination with 1.5 mg/kg 
retinoic acid, resulted in increased survival compared to single agent administration 
[143].  In a second study, daily administration of 150 mg/kg of vorinostat significantly 
inhibited the growth of fribrosarcoma cells in athymic nude mice.  Furthermore, this 
inhibition was dramatically increased by the combination of 2.2 mg/kg of doxorubicin, 
demonstrating again the efficacy of vorinostat in combination with other 
chemotherapies [144].  
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 The main objective of the in vivo studies performed in this study, was to 
investigate if the synergy observed between vorinostat and adaphostin can be 
recapitulated in vivo.  In general, nude mice have been used as an in vivo model for 
solid tumors.  In contrast NOD/SCID mice have been used for hematological 
malignancies, demonstrating to be more effective in this type of cancer [146].  Using 
different NOD/SCID models we studied the synergy of vorinostat in combination with 
adaphostin.   
First, we used NOD-SCID-IL-2Rgnull mice, which were injected with 100,000 
Molt-4 cells per mice.  Directed by previous finding in the literature, we selected the 
drug dose.  Mice were treated thrice weekly with 125 mg/kg of vorinostat [124], 50 
mg/kg of adaphostin [125] or the combination of these doses.  Results demonstrated 
that cell engraftment occurred at week four post-inoculation (Figure 26).  After one 
week of drug administration, mice treated with adaphostin died suddenly.  Subsequent 
experiments demonstrated that high doses of adaphostin administrated frequently 
could induce gastrointestinal (GI) toxicity (Figure 27).  Interestingly, mice treated with 
the combination remained alive for four weeks, suggesting a possible antagonistic 
effect between the two drugs.  After four weeks, we observed a decrease in cell count 
in mice treated with vorinostat and the combination compared to control mice.  
However all mice died at the same time due to leukemia.  Based on these results we 
cannot draw any conclusions.   
Since we suspected adaphostin toxicity, we decided to decrease the dose to 25 
mg/kg of adaphostin and 50 mg/kg of vorinostat.  In a second pilot study using 
NOD/SCID mice, the previously mentioned doses were administrated alone or in 
combination five days a week.  In this occasion we observed GI toxicity in mice treated 
with adaphostin or the combination after two week of treatment.  Decreased doses of 
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12.5 mg/kg of adaphostin delayed the GI toxicity.  In this occasion we started to see GI 
toxicity again after six weeks of treatments.  In term of cells engraftment, we did not 
observe any engraftment.   
For the first time, we report here, GI toxicity as a result of adaphostin treatment 
administrated at 25 mg/kg daily for two weeks.  Limited in vivo studies have been 
reported using adaphostin.  Li et al. studied the pharmacokinetics of adaphostin using 
plasma from different models [125].  These models included mice, rats, dogs and 
human plasma.  They found that adaphostin was most stable in human and murine 
plasma.  In addition, mice were treated with 50 mg/kg of adaphostin using different 
routes of administration.  They concluded that bioavailability following intraperitoneal 
administration was greater than other administration routes [125].  Based on these 
observations we selected the adaphostin dose and administration route.  However we 
observed high toxicity using this dose.  This discrepancy can be explained by the 
treatment duration and the mouse strain. The previous study treated CD2F1 mice 
once at high doses (50 mg/kg) for a few hours [125]; in contrast we treated NOD-SCID 
mice at 25 mg/kg thrice for a week.   
Toxicity tests using different adaphostin doses and administration schedule 
helped us to elucidate the best dose and schedule resulting in 8 mg/kg of adaphostin 
administering thrice weekly.  This dose was consistent with previous studies 
administrating adaphostin in a glioblastoma orthotopic model [147].  Finally, this dose 
was combined with 50 mg/kg of vorinostat, which was administered for five days a 
week, resulting in no sign of toxicity.  
We observed cell engraftment in NOD-SCID-IL-2Rgnull mice after four weeks 
post-injection.  However, NOD/SCID and NOD-Cg-Rag1 mice failed to achieve Molt-4 
engraftment.  Even though studies have demonstrated that NOD/SCID and mice with 
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Rag-1 mutations are better for leukemia engraftments, some factors in these mice can 
affect the engraftment of cancer cells.  Hudson and colleagues performed a 
comparison between Nude, SCID, NOD/SCID and Rag-1 deficient mice [148].  They 
injected different cells from lymphoid malignancies, including Molt-4.  The results 
demonstrated that NOD/SCID mice had better engraftment compared to the other 
mouse strains [148].  However, in contrast to our model, they injected 1 x 107 Molt-4 
cells subcutaneously instead of intravenously.  Furthermore, in order to optimize tumor 
growth, they mixed Molt-4 cells with HT1080 fibrosarcoma cells [148].  While 
subcutaneous injections allow rapid tumor growth, this model does not provide the 
tumor microenvironment to accurately model the disease, which can result in false-
positive results.  In contrast, orthotopic models, where tumor growth arises in the 
tissue of origin, can mimic the disease with more accurately [149].  
Our results demonstrated that NOD-SCID-IL-2Rgnull mice had better cell 
engraftment compared to NOD/SCID or NOD-Cg-Rag1.  Even when NOD/SCID and 
Rag negative mice lack from the majority of the immune system components, they can 
still possess low levels of natural killer (NK) cells.  In addition, studies have 
demonstrated that with aging these mice can develop high levels of immunoglobulin, 
which resulted in decreased engraftment [150].  Furthermore, engraftment of T-lineage 
ALL cells has lower success rates compared to B-lineage cells in these mice [151].  In 
contrast to NOD/SCID mice, NOD-SCID-IL-2Rgnull completely lack NK cells, which 
make this a better model for T-ALL cell engraftment [152]. 
For future directions, the use of NOD-SCID-IL-2Rgnull mice is recommended.  
As a second option and in order to improvement the chances of Molt-4 cells 
engraftment in NOD/SCID mice, Molt-4 can be mixed with HT1080 fibrosarcoma cells.  
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This last approach has been proven to enhance the cell engraftment [151, 153].  In 
addition, further immunosuppression can be achieved using irradiation [148]. 
 
Conclusion and future directions 
In summary, we found that for the first time the ROS generating agent 
adaphostin synergizes with two different HDACi (vorinostat and entinostat) in ALL 
cells. Importantly, the synergistic concentration did not affect normal PBMC, 
demonstrating that this effect is selective for T-ALL cells.  This synergy is mainly 
driven by the activation of the intrinsic apoptotic pathway, where time course analysis 
showed that perturbation of the mitochondrial membrane potential is the earliest event 
observed.  Following this event, increasing levels of superoxide, caspase activation 
and ultimately cell death were observed.   
Pre-treatment with the antioxidant N-acetylcysteine (NAC) blocked ROS 
generation and reversed the loss of mitochondrial membrane potential in both 
combinations. However, apoptosis was only blocked by NAC in cells treated with 
vorinostat-adaphostin; but not with entinostat-adaphostin, suggesting that these 
combinations work by different redox mechanisms.  Previous adaphostin and/or 
HDACi targets, like Trx, GSH, were tested to try to elucidate the source of oxidative 
stress in these combinations.  We concluded that Trx and GSH are not the major 
source of ROS in these combinations.  However gene array data, examining the 
expression of genes involved in oxidative stress, resulted in genes differentially 
regulated between cells treated with vorinostat-adaphostin and entinostat-adaphostin.  
These target genes includes: aldehyde oxidase 1, peroxiredoxin-6, metallothionein, 
angiopoietin-like 7 and glutathione peroxidase-6.  From these a promising candidate to 
follow-up is aldehyde oxidase 1.  This gene is involved in the production of superoxide 
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and drugs metabolism.  This was upregulated in the combination of entinostat plus 
adaphostin but not changes were observed in the combination of vorinostat plus 
adaphostin.    
Future directions include the validation of the different genes, specially AOX1, 
which were differentially regulated between both combinations.  Results from these 
experiments will help to explore different pathways that can be affected by these 
combinations.  In addition the development of an in vivo model is of utmost importance 
to test the clinical relevance of HDACi plus adaphostin combinations for the treatment 
of T-ALL.  Suggestions will be to employ the initially used NOD-SCID-IL-2Rgnull 
mouse model with the dose regimens characterized in our toxicity test.  In addition, the 
use of ALL patient samples can be used as a second alternative to test if HDACi 
synergize with adaphostin.   
Understanding the mechanism involved in these combinations will advance 
scientific knowledge of how the action of HDACi could be augmented in leukemia 
models. Moreover, this information could be used for the development of effective 
clinical trials combining HDACi with other anticancer agents. 
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APPENDIX: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1. Synergistic combinations do not affect XIAP. 
5 x 106 Jurkat cells were treated with the synergistic 
combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada 
and 2.5 µM Enti or either agent alone.  After 24 h of 
incubation cells were harvested and protein lysates were 
prepared. XIAP and total actin were measured by Western 
blot. 
Figure A2. TBP-2 expression in cells treated with the 
synergistic combinations at 4 h and 8 h. 5 x 106 Jurkat 
cells were treated with the synergistic combinations of 0.5 
µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. 
After 4 h and 8 h cells were harvested and RT-PCR for 
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